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ABSTRACT

Sharma, Neelima. Ph.D., Biomedical Sciences Ph.D. Program, Wright State
University, 2014. Apelin Regulation of K-Cl Cotransport in Vascular Smooth
Muscle Cells.

Atherosclerosis and high circulating levels of oxidized low density lipoproteins
(oxLDL) are considered among the most important risk factors for the occurrence
and development of cardiovascular disease (CVD). During the atherosclerotic
lesion repair, phenotypic transition of vascular smooth muscle cells (VSMCs)
from contractile to synthetic states plays a central role. In this process, enhanced
proliferation/migration of VSMCs, from the tunica media to the intima, is required
to sustain blood vessel endothelium integrity, and for inducing vessel wall
remodeling in response to injury. At the molecular level, the activity of
electroneutral potassium-chloride cotransporters or KCCs, is necessary to: a)
allow

changes

in

cell

volume

(key

prerequisites

to

coordinate

cell

proliferation/migration) and b) sustain normal cardiovascular function. Stimulation
of the adipokine apelin and its receptor APJ (apelin/APJ) signaling pathway has
been shown to protect against atherosclerotic lesion formation by lowering blood
pressure levels and promoting vasodilation. Upon binding to APJ, apelin
promotes nitric oxide (NO)-mediated vasodilation, and cell proliferation via the
PI3K/Akt and MAPK pathways. Apelin/APJ exert its action through the same
iii

signaling pathways regulating the KCCs. However, the mechanisms of KCC
regulation by apelin/APJ remain to be determined. Thus, we hypothesized that
KCC expression and activity play an important role during VSMCs’ phenotypic
transition and could be involved in the apelin/APJ cardioprotective effects. In
addition, it is possible that the apelin-mediated effect on KCC activity could also
be dependent on factors affecting the transporter, such as, serum, ionic strength,
osmolality, cell proliferation and migration.
This hypothesis will be tested using rat aortic VSMCs that were immunologically
validated by specific markers. KCC activity was measured by atomic absorption
spectrophotometry using rubidium as a potassium (K+) congener. KCC
expression and transport activity were characterized with respect to the VSMC
phenotypes, in the presence or absence of apelin and corresponding inhibitors of
the signaling pathways, oxLDL and as a function of the various aforementioned
physiological factors.
While markers for the contractile VSMC phenotype are well known, they are less
defined for the early and late synthetic ones. In the present study, we showed a
decrease in expression levels of cytoskeletal proteins like α-actin, desmin and
vimentin in late synthetic VSMCs compared to early states suggesting that the
latter show similar characteristics to the contractile phenotype. In addition, KCC1
and KCC4 protein expression and overall KCC activity increased in late vs early
synthetic VSMCs. The ion binding affinity (Km) for late and early synthetic VSMCs
was similar for K+ whereas it decreased for Cl-. Whether the increase in KCC
activity in late synthetic VSMCs is due to turnover changes of pre-existing KCCs
iv

or enhanced membrane trafficking/insertion of de novo synthesized KCC protein
remains to be studied. Using selective inhibitors, we showed that apelinmediated activation of KCCs occurs through the NO/sGC/PKG pathway in
contractile, and by PI3K/Akt and MAPK dependent pathway(s) in synthetic
VSMCs. Furthermore, apelin rescued the inhibition of KCC induced by oxLDL in
contractile VSMCs. We also showed that the apelin-mediated activation of KCCs
is dependent on extracellular sodium, osmolality, presence of serum in the
growth media, VSMCs phenotype (contractile vs synthetic), and passage
number. Altogether, our results identify apelin/APJ as an important modulator of
KCC activity to sustain cell volume regulation and overall vascular function.

v
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INTRODUCTION
Cardiovascular disease
Cardiovascular disease (CVD) is the leading cause of mortality worldwide (1-3). It
has been estimated that CVD is responsible for over thirty percent of global
deaths and billions of dollars are being spent on its prevention and treatment (4).
CVD includes a number of health problems that affect heart and/or blood vessels
function. Ischemic heart disease and stroke are among the most predominant
CVDs. According to the World Health Organization (WHO), they are responsible
for over 13 million deaths a year (5).

Among the several risk factors that lead to CVD, atherosclerosis (hardening and
narrowing of the blood vessels) plays a pivotal role (6). In brief, endothelial
dysfunction, loss of contractility of vascular smooth muscle cells (VSMCs)
combined with improper handling of low density lipoproteins (LDL) and increased
oxidative stress, result in luminal narrowing and concomitant inflammatory
events. In sum, these processes trigger sub-endothelial accumulation of oxidized
low density lipoproteins (oxLDL), macrophage infiltration and lesion formation
(foam cell appearance and atherosclerotic plaques) (7) (Figure 1).
Since damaged endothelium of blood vessels plays a key role in the occurrence
and developing of atherosclerosis, a brief description of blood vessels’
architecture and VSMCs function will be provided.

1

Figure

1.

Events

leading

to

atheroscleotic

plaque

formation.

Atherosclerosis is the underlying cause of CVD resulting from processes
involving endothelial dysfunction, accumulation of oxLDL, migration of
VSMCs, and infiltration of macrophages among others. Figure modified with
permission from (reference # 8, Madamanchi,N.R. 2005).
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Blood vessels’ architecture
Blood vessels are located throughout the body, and are hollow tubes that
circulate blood to different organs. Functional blood vessels require the formation
of endothelial tubes and recruitment of smooth muscle cells around these
endothelial cells to form a multilayered vessel wall (9). Structurally, blood vessels
are mainly composed of three concentric layers also called “tunica”. The
innermost layer is the “intima”, the middle one is called “media” and the most
exterior one called “adventitia”. The intima outlines the lumen of the vessel wall.
This layer is in direct contact with red blood cells and forms a slick surface to
minimize friction against blood flow. The normal intima of large arteries, like the
aorta, has a continuous endothelial monolayer seated on a basement membrane,
separated from the media by the internal elastic lamina (10). The tunica media
consists of VSMCs, macrophages, and fibroblasts (11). The media is very elastic
and primarily composed of VSMCs arranged circumferentially. The muscle
relaxes to vasodilate and contracts to vasoconstrict the vessel. This allows the
regulation of blood flow. Outside of the tunica media is the adventitia that is
separated from the media by the external elastic lamina. The outermost layer,
adventitia, consists of connective tissue made up of fibroblasts and nerve fibers
(12). The strong connective tissue supports and strengthens the vessel,
connecting it to nearby structures (Figure 2).

3

Figure 2. Composition of vascular wall. Functional blood vessels require
the formation of endothelial tubes and recruitment of smooth muscle cells
around these endothelial cells to form a multilayered vessel wall. The tunica
intima, tunica media, and tunica externa (adventitia), are the three basic
concentric layers of the arterial wall.
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One important feature of the tunica media is its elasticity. When VSMCs
relax/shrink, vasodilation is promoted, whereas when they contract/swell,
vasoconstriction is sustained (13, 14). Regulation of cell volume is necessary to
coordinate vasoconstriction/vasodilation events in order to sustain vascular tone
and proper blood flow (Figure 3).

Vascular smooth muscle cells
VSMCs constitute the major component of the blood vessels’ tunica media. By
controlling changes in their cell volume; they are responsible for modulating
vessel luminal diameters and thus vascular tone (Figures 2 and 3).

The

structural integrity of VSMC is maintained by various components. The plasma
membrane contains multiple invaginations, called caveola. These caveolae
enclose molecules essential for the initiation of signal transduction (15). Gap
junctions in the periphery connect adjacent smooth muscle cells allowing the
transmission of signals from cell to cell (16). A large portion of cytoplasmic
volume is taken up by actin and myosin molecules, and the interactions of these
filaments modulate the contraction of the smooth muscle. In VSMCs, α-actin is
the prevalent actin filament isoform, a component of the contractile machinery
(17, 18). Furthermore, intermediate filaments such as desmin and vimentin also
play a key role in the coordinated relaxation and contraction of VSMCs (19).
Thus, the coordinated interaction between the contractile machinery and
cytoskeleton enables cells to elongate or shorten as needed.

5

Figure 3. VSMCs regulate the vessel luminal diameter. VSMCs are
elastic

in

nature

and

necessary

for

proper

vascular

tone

(vasoconstriction/vasodilation) VSMCs are responsible for controlling the
diameter of blood vessels by changes in their cell volume.
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VSMCs participate in atherosclerotic lesions due to their remarkable capacity to
migrate and proliferate. VSMCs uniqueness relies in their two extreme
phenotypes: contractile and synthetic, with intermediate phenotypes in between
(20-22). VSMCs undergo phenotypic modulation, especially during vascular
injury (Figure 1). The contractile phenotype of VSMCs, which is required to allow
vasodilation and vasoconstriction, is characterized by a robust NO-signaling
casacade. It consists of the nitric oxide (NO)/soluble guanylate cyclase
(sGC)/protein

kinase

G

(PKG)

pathway

involved

in

vasodilation

and

vasoconstriction (23-25). In contrast, the synthetic phenotype, predominantly
expressed in diseased blood vessels,

is characterized by an impaired NO

pathway and overexpression of the mitogen activated protein kinase (MAPK) and
phosphatidylinositol-3-kinase (PI3K)/protein kinase B/Akt pathways both involved
in cell proliferation. The differences in expression of protein markers, signaling
molecules, and rate of proliferation and migration determine the VSMCs
phenotypes (13). The transition from contractile to synthetic favors vascular
remodeling and makes VSMCs an important model system to study
atherosclerosis (23, 26, 27).

Due to their remarkable capacity to migrate, proliferate and differentiate into
extreme different phenotypic states (contractile and synthetic); VSMCs also play
an important role in the repairing of atherosclerotic lesions (20-22). When
atherosclerotic lesions occur, transition from a “contractile” to a “synthetic state”
facilitates proliferation and cell migration. Failure to switch back to a contractile
state accelerates atherosclerotic lesion progression. The phenotypic transition in
7

VSMCs involves different protein expression profiles that are required to sustain
and restore vascular function and cell contractibility (Figure 1). Under normal
conditions, VSMCs can be found in a quiescent state and proliferate infrequently.
Contractile VSMCs undergo phenotypic switching to synthetic states in response
to hypertension, vascular damage, oxLDLs or atherosclerotic lesions (13, 28, 29).

To properly coordinate vasodilation/vasoconstriction events, contractile VSMCs
rely on exquisite rearrangements of actin and myosin molecules along with
intermediate filaments such as desmin and vimentin (17, 18).

The nitric oxide/soluble guanylate cyclase/protein kinase G signaling cascade
(NO/sGC/PKG) is one of the most important regulators of the contractile
machinery (30). When contractile VSMCs differentiate to synthetic states,
(NO/sGC/PKG) becomes unresponsive and upregulation of signaling cascades
involved

in

cell

proliferation

and

migration

takes

place

(MAPK

and

phosphatidylinositol-3-kinase (PI3K)/protein kinase B/Akt pathways) (13) (Figure
4). In addition, synthetic VSMCs exhibit high levels of production of extracellular
matrix proteins needed for vascular remodeling during atherosclerotic injury (23,
26, 27) (Figure 1).

8

Figure 4. VSMCs phenotypic differentiation. VSMCs have two extreme
phenotypes: contractile and synthetic. VSMCs in their contractile state have
a spindle-like elongated morphology, express contractile proteins and
regulate vascular tone. The Nitric oxide (NO)/sGC/PKG pathway is highly
expressed in contractile VSMCs and is responsible for determining the
vasodilation/vasoconstriction levels. Synthetic VSMCs display a fibroblast
like morphology, exhibit high expression of extracellular matrix proteins
(ECM) and are highly proliferative and mobile. PI3K/Akt and Ras/Raf/Erk1/2
MAPK pathways sustain cell proliferation and migration involved in the
progression of atherosclerosis.
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Given that high plasma levels of low density lipoproteins (LDLs) impair VSMCs’
function and vasodilation of blood vessels, a brief discussion of their
characteristics and their role in CVD will be presented.

Low density lipoproteins
LDLs are the principal particles to transport cholesterol and fat in the human
body. They are sphere-like structures (18-25 nm in diameter), made basically of
phospholipid monolayers and apolipoprotein B-100 (Apo B) (31, 32). The
hydrophobic core of LDLs is the site where cholesterol molecules are carried.
During cellular demand for cholesterol, Apo B on the surface of LDLs interacts
with specific receptors and triggers endocytosis to facilitate uptake and utilization
of lipids through lysosomal degradation (33).

Studies have shown that high circulating levels of LDL (over 160 mg/dL) facilitate
cholesterol deposition in the tunica intima which, over time, promotes
atherosclerotic plaque formation and lumen narrowing (34) (Figure 1). Thus,
elevated levels of LDL have been implicated in coronary heart disease.
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Oxidation of Low Density Lipoproteins
The oxidation of LDLs is considered one of the major culprits for the progression
of atherosclerosis and occurrence of CVD (35-37). In brief, oxLDLs accelerate
various pro-inflammatory and pro-atherogenic pathways (38). When LDLs are
oxidized, they cannot be recognized by their “normal” LDL-receptors. Thus, in
order to facilitate oxLDL uptake and its clearance from the tunica media, various
scavenger receptors such as CD36 and LOX-1 are up-regulated (39, 40).

Reports have shown that there are abundant scavenger receptors in
macrophages, endothelial cells and VSMCs. These scavenger receptors play a
crucial role in the uptake of oxLDL. Uncontrolled uptake of oxLDL leads to
morphology changes (appearance of foam cells: fat laden macrophages and
VSMCs) (39, 41, 42). Besides changes in morphology, oxLDLs dramatically
disturb cell function (Figure 5). They support recruitment of monocytes, facilitate
macrophage infiltration, impair nitric oxide (NO) production/vasodilation and
promote VSMCs differentiation, proliferation and migration. Altogether, oxLDLs
profoundly impair normal vascular function and therefore contribute to the
development of atherosclerotic lesions (39, 40).

As part of the repair mechanisms of atherosclerotic lesions; differentiation and
migration of VSMCs is of crucial importance (43, 44). Because oxLDLs have
shown to support the phenotypic transition of VSMCs, a more detailed
examination of VSMCs’ role and function will be described below.

11

Figure 5. oxLDL atherogenic effects on cell function. oxLDL uptake by
scavenger receptors expressed in endothelium, VSMCs and macrophages,
promotes the occurrence and development of atherosclerosis by altering cell
function.
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In vitro primary cultures of VSMCs to study atherosclerosis progression
A time-dependent dynamic phenotyping switch in VSMCs was evident ever since
they were first isolated and cultured in vitro (Figure 4). At initial stages of
subculturing (passage # 1 to 4), cultured VSMCs display ribbon-like elongated
shapes with high resemblance to the cells from intact tissue. Early in vitro
VSMCs cultures exhibit high density of myosin filaments with close resemblance
to contractile VSMCs in vivo. After several days in culture, the expression of
myoﬁlaments decreases, and the cells begin to resemble the “synthetic” cells
seen during blood vessels’ regeneration and atherosclerotic plaques (45).

In vivo, contractile VSMCs undergo phenotypic switching due to stimuli like
hypertension, vascular damage, exposure to oxLDLs or atherosclerotic lesions;
in vitro, the phenotypic status of VSMCs is determined mainly by passage
number or incubation with certain mitogens or growth factors (e.g., oxLDL,
PDGF) (21, 22, 46-48). The possibility to obtain and track in vitro the transition of
VSMCs to synthetic/diseased stages makes the usage of VSMCs extremely
helpful in obtaining a better understanding of the progression of atherosclerotic
lesions.

Apelin/APJ cardioprotective role
Recently, the signaling pathway (apelin/APJ), involving the adipokine apelin and
its G-protein coupled receptor (APJ), has emerged as a potent regulator of
cardiovascular function (49-51). Apelin, is generated in vivo as a 77 amino acid
precursor (pre-proapelin) that is cleaved to generate functional shorter peptides,
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(Apelin-13,-16,-17,-19 and 36) among which, apelin-13, exhibits the highest
activity and concentration in the circulatory system (52-54) (Figure 6).
Additionally, the apelin peptide undergoes posttranslational modification which
results in the addition of pyroglutamate to the N terminus region producing (pyr 1)
apelin-13 peptide. The pyroglutamation protects the peptide from exopeptidase
degradation and preserves its biological activity (55).

APJ Receptor
The Apelin receptor (APJ) is a 7 transmembrane (TM) domain structure that
belongs to the G-protein coupled receptor (GPCR) family. The receptor is
expressed

in

numerous

tissues,

including

heart,

lung,

liver,

kidney,

gastrointestinal tract, brain, adrenal gland, endothelium and smooth muscle. The
gene encoding for APJ designated APLNR encodes for a 380-amino acid protein
and is located on chromosome 11q12 (56, 57). APLNR is evolutionary conserved
among species (57, 58). The APJ receptor shares 54% of identity in the TM
region and 30% overall with the angiotensin II (Ang II) receptor, AT 1 (56). Even
though there is high identity between the APJ and AT 1 receptors, the Ang II
molecule does not bind to the APJ receptor (51).

Upon binding to its receptor, apelin-13 triggers a plethora of signaling cascades
and changes in protein expression that have proven to be beneficial against CVD
(52). Among its cardio-protective effects, scientific evidence highlights: strong
anti-hypertensive and anti-atherogenic properties; all of them associated with
several intracellular signaling cascades such as: a) NO/sGC/PKG pathway, b)
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the PI3K/Akt, and c) the mitogen activated protein kinase MAPK signaling
network Ras/Raf/Erk (51, 53, 59-63).

Apelin administration antagonizes the hypertensive effect of Ang II in vascular
complications like atherosclerosis by increasing NO levels (51, 64, 65). Apelin
also has ionotropic effects by increasing the heart rate and contractility of
isolated and intact hearts of mice and rat (66, 67). Binding of apelin to APJ
alleviates hypertension and has a protective effect in ischemic heart disease.
Several in vivo and in vitro models have revealed a potential role of apelin in
cardiovascular function, for instance, in knockout mice models for apelin,
impaired cardiac contractility and occurrence of CVD have been observed (68).
Studies have shown that apelin acts as a potent angiogenic factor promoting
proliferation of VSMCs and endothelial cells (69-71). Consistent with its role
promoting cell proliferation, apelin has proven to suppress via PI3K/Akt apoptotic
cell death. Both apelin and APJ are needed for cardiovascular development and
formation of heart morphology (65). Recent evidence has pointed out that
apelin/APJ system plays a critical role in the homeostatic balances of numerous
processes (58, 64, 72). Overall, increasing evidence points out the central role of
apelin/APJ in cell function; placing it as a potential therapeutic target for the
treatment of CVD (53, 73) (Figure 7).
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Figure 6. Apelin processing.

Amino acid sequence of different apelin

peptides isoforms. A. (pyr1) apelin-13, B. apelin-13, C. apelin-17 and D. apelin36. Figure adapted with permission from (reference # 52, O'Carroll,A.M. 2013).
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Figure 7. Cardioprotective effects mediated by apelin/APJ. Apelin and APJ
signaling contribute to normal cell function in blood vessel and adipose tissue.
Figure modified with permission from (reference # 74, Barnes,G. 2010).
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As mentioned earlier, VSMCs differentiation, proliferation and migration are key
during the repairing process of atherosclerotic plaques. At the molecular level,
the coordinated activity of members of the solute carrier family 12A (SLC12A) is
central to controlling cell volume and thereby cell proliferation and migration.
Therefore in the following paragraphs the role and activity of SLC12A members
will be discussed.

SLC12A-Cation Chloride Cotransporters
Members of the SLC12A are among the most important mechanisms to
coordinate osmotic water influx and efflux. Based on homology and sequence
identity, the SLC12A family is composed of at least eight cation chloride
cotransporters (CCCs) members: three Na+-dependent inwardly oriented (NCC,
NKCC1 and NKCC2), four outwardly oriented K+-dependent and Na+independent (KCC1 to 4), a cation chloride cotransporter interacting protein (CIP)
and probably the polyamine transporter (CCC9) (75, 76) (Figure 8). Tight control
of cell volume is of paramount importance to sustain normal cell function and
survival (77).
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Figure 8. SLC12A family of cation chloride cotransporters. Schematic
representation of SLC12A members of cation-chloride cotransporter. The
potassium-driven chloride cotransporter (KCC1-4) mediate the efflux of
chloride. NKCCs and KCCs participate actively in RVD and RVI by promoting
the osmotic transport of water across the cell membrane.
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When cell volume is perturbed, volume restoration mechanisms are activated in
order to maintain cellular homeostasis. These mechanisms involve the
coordinated function of CCC, channels, exchangers and sodium potassium
ATPase (i.e. Na+/K+ pump) to change the intracellular concentration of organic
and inorganic osmolytes and ultimately the osmotic influx/efflux of water.
Efflux of potassium (K+), chloride (Cl-) and organic osmolytes takes place to bring
cell volume back to normal to counteract the exposure to hypotonic extracellular
conditions that would lead to uncontrolled cell swelling. This volume restoration is
achieved through stimulation of: K+ and Cl- channels, along with K+-Clcotransporters (known collectively as KCCs). Altogether they mediate the exit of
K+ and Cl- associated with water efflux (78-80). Similarly, when cells are exposed
to hypertonic stimuli and as a way to prevent cell shrinkage, a series of events
known as regulatory volume increase response (RVI) are triggered to increase
the intracellular osmolyte concentration and water influx. RVI results in
restoration of cell volume through activation of the sodium/potassium (Na +/K+)
pump, sodium-potassium-two chloride (Na+-K+-2Cl-) cotransporter (NKCC), along
with chloride/bicarbonate (Cl-/HCO3-) and sodium/proton (Na+/H+) exchanger (81,
82) (Figure 9).
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Figure 9. Regulatory mechanisms to keep cell volume constant. During
hypotonic or hypertonic challenges, RVD or RVI response take place to prevent
cell death by cell swelling or shrinkage. During RVD, KCCs’ activity is
upregulated to facilitate water osmotic efflux whereas NKCCs’ activity is
necessary to promote water influx during RVI.
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The Cation-Chloride Cotransporters (CCCs) and the Na+/K+ pump
The CCCs are secondary active transporters, as there is no ATP utilization and
therefore rely on the chemical gradient generated by the Na+/K+-ATPase to move
Cl- against its electrochemical gradient (83-86). Structurally, they are predicted to
have 12 transmembrane segments and long intracellular amino and carboxy
termini. Normally, NKCCs transport ions at a ratio of 1Na+:1K+:2Cl-, NCC at a
ratio of 1Na+:1Cl-, and KCCs at 1K+:1Cl- ratio. The stoichiometry for all CCC
results in electroneutral movement as the net charge traversing the plasma
membrane is zero and thus, they are classified as electroneutral cation-coupledanion transporters (76, 87). These cotransporters share a 47-60 % identity in
amino acids among each other (88).

In VSMCs, expression of several members of the SLC12A has been reported
(89-91). NKCC1, KCC1, 3 and 4 actively participate in several cellular processes
such as regulation of cell volume, differentiation, motility and proliferation (91).
NKCC1 is a protein of 1212 amino acids, encoded by the SLC12A2 gene located
on chromosome 5q23 (92). NKCC1 exhibits ubiquitous expression and is target
of tissue specific posttranslational modifications (glycosylation) that result in
proteins ranging from 135 kDa to 195 KDa (93). NKCC1 is known to function as a
homodimer and is predicted to have a hydrophobic core of 12 TMD and long Nand C-terminal cytoplasmic domains. They bear a long hydrophilic extracellular
loop (ECL) between TMD 7 and TMD 8 which is target for glycosylation (92, 9496). NKCC1 activity can be inhibited by loop diuretics bumetanide and
furosemide. To date, the precise binding site for bumetanide has not been
22

resolved. Using chimeric protein approaches and point mutation strategies, it is
believed that they are localized across the hydrophobic core of the TM domain.
Cation binding is primarily localized on TM2 domain, Cl- binding involves TM4
and TM7 domains, and bumetanide binding includes multiple domains
comprising TM2, TM7, TM11 and TM12. The N- and C- termini do not participate
in ion binding (97-99).

NKCC1 activity is tightly linked to its phosphorylation state. Phosphorylation of
three N- terminal threonine residues (Thr-184, 189 and 202) and Thr-1114 on the
C-terminal regions have been identified as modulators of NKCC1 trafficking and
activity (93-95, 100).

These sites are phosphorylated via two serine threonine kinases: the Ste-related
proline-alanine-rich kinase (SPAK) and the oxidative stress response 1 kinase
(OSR1). Protein phosphatase 1 (PP1) removes these phosphates and
inactivates the cotransporter. These protein kinases and phosphatases physically
interact with NKCC1 through overlapping binding motifs within NKCC1 N-terminal
region, highlighting a coordinate modulation of the NKCC1 activity (Figure 10)
(101).

Besides NKCC1, VSMCs highly express several KCCs (KCC1, 3-4) and very low
levels of KCC2, which actively participate in modulating cellular volume and ionic
homeostasis (102-105). Apelin relevance in regulating the three signaling
pathways described in the preceding sections lies in the fact that the newly
discovered ion transporter, KCC was initially co-discovered and characterized in
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detail by Drs. Peter Lauf and Norma Adragna from our laboratory in the US and
by Drs. Clive Ellory and Philip Dunham in the United Kingdom (90).

The KCC share roughly 30 % identity in amino acids with other CCCs family
members. Their primary structure is predicted to be of 12 trans-membrane (TM)
domains with both N and C termini located in the cytoplasm and a glycosylated
extracellular loop between TM 5 and TM 6 (76, 88, 106-108). The 12 TM
segments are highly-conserved regions, and the C-terminus domain is even
more conserved compared to the N-terminus domain. The cation binding sites in
TMD2 have been established through chimera work, whereas, the anion binding
sites are less defined, involving several domains of the molecule (88, 97). Both N
and C-termini domains have consensus phosphorylation sites for kinases and
phosphatases and are involved in signal transduction (Figure 10) (76).

The

transporter is highly selective for K+ and Cl- ions, possesses asymmetric kinetics
in ion binding, mediates the electroneutral transport of ions and is important in
cell volume regulation (109, 110).

The modulation of KCC activity involves dephosphorylation of serine/threonine
residues located within the amino and carboxy termini. Thus, the coordinated
activity of kinases and phosphatases is important to sustain normal KCC function
(111). Protein phosphatase 1A and 2B along with members of the “with no lysine”
(WNKs) and STE20 (SPAK) serine kinase family are important modulators of the
activity of KCCs and NKCCs (112-115). These proteins and kinases reciprocally
regulate KCC and NKCC activity (116, 117). Coordinated modulation of NKCC
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and KCC by these kinases and their involvement in controlling in cell volume is
summarized in (Figure 10).

Figure 10. Coordinated regulation of K-Cl cotransporters (KCCs) and NaK-2Cl cotransporters (NKCCs). Phosphorylation/dephosphorylation events
control the activity of NKCCs and KCCs during changes in osmolarity.
PP1A/PP2 mediated dephosphorylation inhibits NKCC and activates KCC.
The serine threonine kinases WNK and SPAK phosphorylate NKCCs and
promote their activation.
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KCC is a ouabain- and bumetanide-insensitive transporter that mediates coupled
K+ and Cl- bidirectional transport across the membrane (107-110). Although the
transporter functions bi-directionally, under physiological conditions, KCC is
mainly directed outward (118).

An important feature of KCC is its ability to be stimulated by cell swelling or by
treatment with N-ethylmaleimide (NEM) (84, 119, 120). KCC activation by
hypotonicity was initially observed in red blood cells and then later discovered in
different cells of various species (120). In various cell systems, NEM selectively
activates KCC (121, 122, 122-124). Both NEM and hypotonicity-stimulated cell
swelling have been used as diagnostic criteria to identify the functional presence
of KCC.

To date, four KCC isoforms have been identified: KCC1, KCC2, KCC3 and KCC4
with their distinct tissue specific expression. KCC1 and KCC3 share 75 % identity
in their amino acids; whereas, KCC2 and KCC4 share 72 % identity in their
amino acid residues (125, 126). Additionally, these isoforms are also capable of
interacting with each other or one another resulting in the formation of homooligomers or hetero-oligomers, respectively, most likely involving the last Cterminal residues (127-129).

KCC1 is encoded by the SLC12A4 gene located on chromosome 16q22 (88).
The expression of KCC1 is ubiquitous (housekeeping isoform) and plays a role in
cell volume regulation acting in reverse direction of NKCC1. While NKCC1 plays
a role in RVI when the external osmolarity increases, KCC1 plays a role in RVD
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by enabling K+ and Cl- to exit the cell (88, 130, 131). The predicted structure of
KCC is similar to NKCC except that the extracellular hydrophilic loop containing
glycosylation sites are linked to TMD5 and TMD6.

The KCC2 transporter was originally cloned from a mouse brain cDNA library
(106). The protein is composed of 1116 amino acids residues and this isoform is
encoded by the SLC12A5 gene located on chromosome 20q13. Although initial
findings suggested localized expression in CNS due to a neuronal-restrictive
silencing element (NRSE), recent evidence has shown its expression in
metastatic processes and minimal mRNA expression documented in VSMCs (75,
88, 104, 106, 125, 132, 133, 133-138). Unlike KCC1, KCC2 activity is not
sensitive to cell volume and thus, is not stimulated upon cell volume. KCC2
function in conjunction with NKCC1 and KCC3 to maintain neuronal excitability
by regulating intracellular Cl- concentration. Due to differential expression of
NKCC1 and KCC2 during the development of the central nervous system; in
embryonic immature neurons, intracellular [Cl-] is high due to increase in activity
of NKCC1. As the neurons undergo maturation, the expression of NKCC1
declines and is switched by KCC2 that extrudes Cl- (139). This switch allows
operation of γ-aminobutyric acid (GABA) receptors to induce depolarization in
developmentally immature neurons and hyperpolarization in mature adult
neurons. KCC2 knockdown models display epilepsy (140, 141).

KCC3 consists of 1150 amino acids residues and is encoded by the SLC12A6
gene located on chromosome 15q13-14 (135). The isoform is fairly expressed in
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brain, muscle, kidney, liver, lung and heart. KCC3 mutations have been
associated with Anderman’s disease. KCC4 is encoded by SLC12A7 gene that is
located on chromosome 5p15.3 and is mainly expressed in kidney, heart, smooth
muscle cells and to a slighter extent in the brain. KCC4 has been linked to inner
ear function (125).

The broad arrays of the physiological roles of each of the KCC isoforms have
been studied by gene disruption in mice and the resulting phenotypes observed
were linked to various human diseases. KCC1 and KCC3 are implicated in
hemoglobinopathies. KCC3 is implicated in hypertension, KCC2 is associated
with epilepsy, and KCC4 is linked to hearing disorders (76, 137, 142-145). The
functions of each of the isoforms are shown in Table 1.

VSMCs have three of these four isoforms: KCC1, KCC3 (splice variants KCC3a
and KCC3b), and KCC4 (102, 103). KCC2a but not KCC2b, which is neuron
specific KCC2 has been documented as fairly expressed in VSMCs and lens
epithelial cells (132, 138). It is possible that the expression of different isoforms in
VSMCs varies in quantity in pathological conditions.
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Table 1. Summary of KCC isoform-specific distribution and function (76,
118, 146).

{{688 Gagnon,K.B. 2013; 64 Lauf,P.K. 2000}}.
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KCC and signaling pathways in relation to CVD
A substantial body of evidence suggests a role of KCC in general cellular
homeostasis, hypertension, blood pressure regulation and cell proliferation
stressing the need to study KCC in relation to CVD and cellular homeostasis (75,
89, 118, 134, 145, 147).

Important modulators of the expression and activities of KCC involve the
NO/cGMP/PKG pathway (75, 102-105, 148). In addition, PDGF uses PI3K/Aktmediated pathway in vascular smooth muscle cells (VSMCs) to regulate KCC
(149,

150).

Furthermore,

phosphoinositol/PKC

KCC1

pathway
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and
low-K

KCC3
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regulated
cells

via

(151).

the
The

NO/cGMP/PKG pathway leads to vasodilation and activates KCC, which in turn,
plays an important role in blood pressure regulation, as shown by a hypertensive
phenotype in mice with deletion of the KCC3 isoform (KCC3 -/-) (89, 102, 137,
145, 145, 145, 152).

In addition to regulating KCC, the NO-mediated pathway regulates VSMC
proliferation, migration, apoptosis, extracellular matrix protein formation, and
relaxation (153-155). The NO-pathway is also important in preventing
atherosclerosis lesions and is activated only if VSMCs are contractile in vitro, i.e.
before passage 4 given that PKG expression diminishes after this passage (22,
25). The activators of the pathway, such as sodium nitroprusside (SNP),
NONOates (NO donors), YC-1 (NO-independent activator of sGC), 8 Br-cGMP
(soluble substrate of PKG) and inhibitors such as LY83583 (for sGC) and
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KT5823 (for PKG), stimulate and inhibit KCC activity, and mRNA and protein
expression, respectively (89, 102-105, 137, 137, 152). Additionally, our
laboratory has shown an association between KCC and atherosclerosis using the
synthetic VSMCs as a model system, where the MAPK and PI3K/Akt signaling
pathways play a prominent role (149, 150).

Regulation of KCC by the PI3K/Akt pathway has been documented by our
laboratory. Platelet derived growth factor (PDGF), a serum mitogen, has a
regulatory role in the pathogenesis of atherosclerosis. In addition, PDGF
stimulates KCC through PI3K/Akt and protein phosphatase 1 (PP-1) and induces
VSMC proliferation (149, 150). The stimulation of KCC was blocked by a
selective inhibitor of the pathway, suggesting regulation of KCC by the PI3K/Akt
pathway (75, 149, 150). Finally, regulation of KCC by MAPK, initially documented
in sheep red blood cells and was later confirmed in successive studies on
cervical carcinoma (134, 151, 156, 157). In these studies, KCC stimulation was
blocked by PD98059, a MEK selective inhibitor, and furthermore, knockdown of
KCC decreased cervical cancer proliferation and activation of the MAPK
signaling cascade suggesting an interdependent relationship between the MAPK
pathway and KCC (151, 158-160).

KCC in cell proliferation/migration
Several studies have suggested serum as an important modulator of ion
channels and transporters (150, 161, 162). Serum contains mitogens and growth
factors that have been shown to regulate activity of channels and transporters in
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various cultured cells. Evidence from our laboratory and others has also shown
regulation of KCC by growth factors or mitogens that is involved in cell
proliferation. Serum factors were essential for basal KCC activity maintenance
(150). Serum deprivation for twenty four hours abolished KCC activity; however,
the effect was recovered after serum addition. PDGF (platelet derived growth
factor), a major mitogen/growth factor for cells of mesenchymal origin present in
serum, is also prevalent in atherosclerotic lesions. PDGF, a potent chemoattractant induces cell proliferation in VSMCs during atherosclerosis. In cell
culture, PDGF utilizes a MAPK pathway to initiate cell proliferation. Our
laboratory has demonstrated that PDGF activates KCC in a time- and dosedependent manner: both acutely and chronically via a PDGF receptor (149, 150).
Primarily, PDGF increases overall protein content in cultured VSMCs
demonstrating the effect of PDGF on cell proliferation, which is an important
mechanism observed during atherosclerosis. Since VSMCs migration is an initial
step in formation of atherosclerotic lesions, evidence of KCC in cell migration has
been documented in studies involving various models.

Cell migration is important in several physiological and pathophysiological
processes including cell volume regulation, embryogenesis, tumor metastases,
wound healing, inflammation, immune defense, atherosclerosis and tissue
remodeling (163). Several lines of evidence have demonstrated KCC playing a
vital role in cell migration (163-165).
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Previous research has shown an interrelationship between cell migration and
KCC activity studies using cancer cell lines showed. An insulin-like growth factor1 (IGF-1) receptor has been shown to regulate KCC production by activating
PI3K and Erk1/2 MAPK pathways in cancerous cells (133, 157, 164). Knockdown
of KCC significantly reduced cell migration. This indicates the importance of KCC
to modulate IGF-1-dependent cell migration and invasion in cancer.

KCCs and apelin
Noteworthy, similar and overlapping regulatory networks converge to regulate
apelin-mediated effects and potassium-chloride cotransport by KCCs, the latter
being ultimately determined through phosphorylation /dephosphorylation events.
For instance, high levels and dysregulated oxLDL uptake by the fatty acid
translocase CD36 (atherosclerosis hallmark), result in pronounced upregulation
of KCC1 (166). At the molecular level, KCCs activity has been shown to be
modulated by the NO, PI3K/Akt and MAPK/ERK1/2 signaling networks, through
which apelin elicits its cardioprotective effects (89, 137, 145, 152). Altogether,
the evidence presented in this thesis suggests a strong link between apelinmediated cardioprotective effect and KCC activity (Figure 11). Since KCC
activity has proven to be required for controlling cell volume, migration,
proliferation and vascular remodeling, we endeavor in establishing a connection
between apelin and KCC function.
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Figure 11. SLC12A family of Cation Chloride Cotransporters. Overlapping
signaling cascades regulate the activity of K+-Cl- cotransporters and apelin
cardioprotective effects.
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DEVELOPMENT OF THE HYPOTHESIS
Apelin/APJ is an important modulator of fluid homeostasis and cell volume. Its
stimulation displays important cardio-protective functions by reducing blood
pressure levels and counteracting the effect of oxLDL. In atherosclerosis, VSMCs
migration/proliferation in combination with high circulating levels of oxLDL
accelerates atherosclerosis progression and blood vessels lesion formation.
Since cell migration/proliferation and cell volume are tightly linked to K-Cl activity,
and extensive overlap exists between the apelin-mediated signaling pathways
(NO, PI3K/Akt, MAPK) and K-Cl cotransport mode of regulation: I hypothesize
that oxLDL and apelin/APJ are important modulators of K-Cl activity to
sustain cell volume regulation, and normal cardiovascular function. In
addition, because K-Cl cotransport activity is dependent on several factors,
such as, serum, ionic strength, osmolality, cell proliferation and migration,
it is possible that the apelin-mediated effect on K-Cl cotransport could also
be dependent on the aforementioned factors.

GOAL: To obtain a better understanding of K-Cl cotransport activity in VSMCs
and to establish whether apelin/APJ exerts an effect on K-Cl cotransport activity
and

whether this effect

is modulated by other physiological factors.
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SPECIFIC AIMS

Specific Aim 1: To characterize K-Cl cotransport in VSMCs and to examine a
possible link to VSMCs phenotype.
Since

synthetic

VSMCs

are

highly

proliferative

and

cell

migration/proliferation strongly relies on K-Cl cotransport and dynamic
rearrangements of cytoskeletal proteins, it is likely that during VSMCs’
dedifferentiation, changes in K-Cl cotransport expression and activity, and
expression of cytoskeletal markers take place to sustain VSMCs’ transition
to synthetic states.

Specific Aim 2: To determine the acute and chronic effect of apelin on K-Cl
cotransport activity in VSMCs. To establish the involvement of NO, PI3K/Akt and
MAPK signaling pathways in the regulation of the transporter.

Specific Aim 3: To assess the factors, such as, serum, osmolality, ionic
strength, VSMCs phenotypes on apelin-mediated effect on K-Cl cotransport
activity. The above factors will shed light on possible variability in the apelin
response on K-Cl activity.
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MATERIALS AND METHODS
Chemicals. Rubidium chloride (RbCl, 99.8 % purity metal basis) and
amidosulfonic acid (99.99 % purity, metal basis) were purchased from Alfa Aesar
(Ward Hill, MA). Potassium chloride (KCl), sodium hydroxide (NaOH),
magnesium chloride (MgCl2), 2-[4-(2-hydroxyethyl)piperazin-1-yl] ethanesulfonic
acid (HEPES), Tris, D-glucose, sucrose, calcium chloride (CaCl2), calcium
gluconate, N-methyl D-Glucamine (NMDG), Minimum Essential Medium (MEM)
Alpha Medium, low glucose Dulbecco’s Modified Eagle’s culture medium
(DMEM), fetal bovine serum (FBS), 0.25 % trypsin, Western blot gel loading
buffer (10X), molecular weight protein ladder, and 70 % perchloric acid (PCA)
were procured from Thermo Fisher Scientific (Waltham, MA). Penicillin (10,000
units/mL), streptomycin (10,000 µg/mL) and cesium chloride (CsCl) were
acquired from Life Technologies (Carlsbad, CA). Magnesium gluconate, 3-[Nmorpholino] propane sulfonic acid (MOPS), and bovine serum albumin (BSA)
were purchased from Sigma-Aldrich (St. Louis, MO).

Bicinchonic acid (BCA) protein kit, mammalian protein extraction reagent (MPer), radioimmunoprecipitation assay (RIPA) buffer, Halt protease inhibitor and
enhanced chemiluminescence (ECL) substrate were from Pierce (Rockford, IL).
Ouabain octahydrate was purchased from EMD Millipore (Billerica, MA).
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Bumetanide was acquired from MP Biomedicals (Solon, OH). Apelin-13 (catalog
# 60833) was acquired from Anaspec (Fremont, CA). Inhibitors of the PKG,
PI3K/Akt and MAPK signaling pathways (KT5823 (catalog # 420321), LY294002
(catalog # 19-142) and PD98059 (catalog # 513000), respectively) were
purchased from Calbiochem (Billerica, MA). oxLDL (catalog # STA-214) was
purchased from Cell BioLabs (San Diego, CA). Collagenase type II (catalog #
171049-019) was purchased from GIBCO BRL (San Francisco, CA).

Antibodies. Polyclonal rabbit anti-PKG antibody was purchased from BioVision
(San Francisco, CA). Mouse (ms) anti-α-actin and rabbit (rb) monoclonal antivimentin were from Cell Signaling (Danvers, MA). ms anti-β-actin was acquired
from Santa Cruz (Dallas, TX), and ms anti-desmin was procured from BD
Pharmigen Co (San Jose, CA). Rabbit polyclonal anti-apelin receptor (APJ) was
purchased from EMD Millipore (Billerica, MA). Rabbit polyclonal KCC4 antibody
was purchased from Chemicon International. KCC1 non-commercial antibody
was generated by traditional rabbit immunization procedures developed by
Gagnon and Lauf (167). Epitope used to raise KCC1 antibody corresponded to
sequences within third extracellular loop (ECL3) (167).

Extraction of primary cultures of VSMCs. Enzymatic dispersion of rat aortic
VSMCs was performed as previously described (150). Aortas from Sprague
Dawley rats (150-200 g) were washed three times in Minimum Essential Medium
(MEM) alpha medium. Then, aortas were mechanically stripped of fat and
connective tissue and treated with collagenase II for 30 min at 37 °C. After
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mechanically removing the tunica adventitia, tissue was cut into smaller
segments and incubated at 37 °C with a trypsin and collagenase II solution until a
single cell suspension was obtained (Figure 12). Cells were centrifuged and
resuspended in DMEM medium containing 10 % fetal bovine serum (FBS), and
diluted to obtain a final concentration of 4 x 105 cells/mL. Finally, cells were
plated into 75 cm2 tissue culture flasks (T-75) and grown in DMEM containing 10
% FBS and supplemented with penicillin (50 units/mL) and streptomycin (50
µg/mL) at controlled atmosphere of 95% O2/ 5% CO2 at 37 oC. Growth media
was replaced every two days until cells were 100 % confluent. Standard
trypsinization was performed to split cells (1:4 ratio) into new T-75 flasks or 12well plates, depending upon the experimental requirements. Cells at passages 14 were considered as contractile VSMCs, whereas passages 6-75 were used as
synthetic VSMCs based on previous phenotype characterization reports as
discussed in the result section.
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Figure 12. VSMCs isolation from Sprague Dawley’s thoracic aorta.
Single VSMCs were isolated by incubating aorta with a collagenase and
trypsin solution.
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Solutions used for Rubidium (Rb+) transport studies.
Several buffers were used during the transport studies to determine K-Cl
cotransport activity. Examination of Rb+ transport under isotonicity was
performed by incubating VSMCs in a balanced salt solution (BSS-NaCl)
composed of 20 mM HEPES-Tris buffer (pH 7.4 at 37 oC) containing (in mM):
NaCl (130), KCl (5), CaCl2 (2), MgCl2 (1), glucose (10). The preincubation
solution contained 0.1 % BSA in BSS. The flux solution replaced 5 mM K + with
10 mM Rb+.
The Cl--free media contained sulfamate (Sf -) in the K+, Rb+, and Na+ salts, and
gluconate in Mg+2 and Ca+2 salts. Na+-free media contained: NMDG in Cl- or Sfsalts. A wash buffer to terminate Rb+ uptake was composed of 10 mM MOPSTris, MgCl2 of pH 7.4 (300 mOsM). Osmolality was changed by varying the ionic
strength of the solution with variable amounts of NaCl, NaSf, NMDGCl or
NMDGSf salts while keeping the other ions constant. In some experiments,
osmolality was increased by using sucrose maintaining the constant ionic
strength. Osmolality (in mOsm/kg H2O) of the hypotonic, isotonic and hypertonic
solutions were 120, 300 and 450, respectively. Ouabain (2 mM) and bumetanide
(2-30 µM) was used to fully inhibit Rb+/K+ fluxes by the Na+/K+ pump and the
sodium-potassium-two chloride cotransporter (Na+-K+-2Cl-) activities, respectively
(Figure 13).

All stock salt solutions were prepared in deionized water. Stock solutions of the
drugs: 400 mM ouabain, 400 µM bumetanide and 0.1 M NEM, KT5823,
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LY294002, PD98059 were prepared in DMSO as solvent. The osmolalities
(osmol/kg H2O) of the salt solutions were measured with Advanced MicroOsmometer (Norwood, MA).
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Figure 13. Schematic representation of various K+ transport mechanisms
in VSMCs. Potassium chloride cotransport (KCCs) can be inhibited by
furosemide or chloride (Cl-)-free media. In our experimental design, the anion
sulfamate (Sf-) was used to study the “leak” pathway represented by other K +
channels that might be present in VSMCs. K-Cl Cotransport corresponds to the
differences in Rb+ influx in Cl- and sulfamate (Sf-) media in the presence of
ouabain and bumetanide to inhibit the Na+/K+ pump and NKCC activity,
respectively.
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Rb+ transport studies. K-Cl cotransport activity was measured using previously
established protocols in VSMCs with slight modifications (150, 152). Confluent
monolayers of VSMCs grown into 12 well plates were rinsed three times with
BSS and then equilibrated for 10 min in preincubation media. Several flux
timeframes (from 0-40 min) were used to determine K-Cl cotransport activity,
which was normalized to protein concentration. Addition of ouabain and
bumetanide during preincubation and flux periods prevented K +/Rb+ movement
mediated by Na+/K+ pump and Na+-K+-2Cl- cotransporters, respectively. Rb+ flux
was terminated by washing cells with ice cold 10 mM MOPS-Tris, MgCl2.
Intracellular Rb+ was released from cells by incubating them in 5 % PCA-4 mM
CsCl 15 min at 4 oC and measured by using a Perkin-Elmer 5000 Atomic
Absorption Spectrophotometer (AAS) in the emission mode (148, 150). Next,
cells were solubilized with 1N NaOH for 30 min at room temperature and protein
concentration was determined using BCA protein assay. Quantification of protein
was performed using Labsystems Multiskan MCC/340 plate reader following
manufacturer’s guidelines (Figure 14). The difference between Rb + transport in
the presence of Cl- and Sf- was used to determine Cl--dependent Rb+ influx (i.e.
K-Cl cotransport activity).
Apelin studies. Previously described Rb+ flux studies were performed with minor
changes: When required, VSMCs were serum deprived for 24 h at subconfluence prior to an experiment. Apelin (1 µM) was added either during flux
and/or in the growth media based on the experimental goals and design (see
result section).
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Solutions for Rb+ transport studies (e.g., Na+ containing solution)
Initial wash solutions
Balanced salt solution (BSS-NaCl):

20 mM Hepes-Tris, 5 mM KCl, 2 mM

CaCl2, 1 mM MgCl2, 10 mM glucose and NaCl, pH 7.4, 37 oC, 300 mOsM.
BSS-NaSf: 20 mM Hepes-Tris, 5 mM KSf, 2 mM calcium gluconate, 1 mM
magnesium gluconate, 10 mM glucose and NaSf, pH 7.4, 37 oC, 300 mOsM.
Preincubation solutions
BSS-NaCl-BSA: 20 mM Hepes-Tris, 5 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 10
mM glucose, 0.1% BSA and NaCl, pH 7.4, 37 oC, 300 mOsM.
BSS-NaSf-BSA: 20 mM Hepes-Tris, 5 mM KSf, 2 mM calcium gluconate, 1 mM
magnesium gluconate, 10 mM glucose, 0.1% BSA and NaSf, pH 7.4, 37 oC, 300
mOsM.
Flux solutions
BSS-RbCl-NaCl-BSA:

20 mM Hepes-Tris,10 mM RbCl, 2 mM CaCl2, 1 mM

MgCl2, 10 mM glucose, 0.1% BSA and NaCl, pH 7.4, 37 oC, 300 mOsM.
BSS-RbS-NaSf-BSA: 20 mM Hepes-Tris, 10 mM RbSf, 2 mM calcium gluconate,
1 mM magnesium gluconate, 10 mM glucose, 0.1% BSA and NaSf, pH 7.4, 37
oC,

300 mOsM.
Final wash solution

10 mM MOPS-Tris, MgCl2, pH 7.4, 4 oC, 300 mOsM.
Rb+ extraction
5% perchloric acid (PCA), 4 mM CsCl
Protein extraction
1M NaOH
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Figure 14. Summary of steps for assessing Rb+ influx in VSMCs. Washed
VSMCs were loaded with Rb+ (5-40 min), then Rb+ ion was extracted by PCA
and ion concentration was measured by AAS. Protein was solubilized by 1 N
NaOH and the content was determined by BCA protein assay.
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Protein extraction. Total extracts from VSMCs were obtained using either MPER and/or RIPA lysis and extraction buffers (Pierce Biotechnology). In all cases
manufacturer’s guidelines were followed accordingly. VSMCs were grown into
100 mm petri dish. Confluent monolayers were rinsed with cold PBS and
resuspended in lysis buffer at 4 oC in the presence of protein-phosphatase and
protease inhibitors. Total cellular protein extracts were obtained using a cell
scrapper, then sonicating 5 pulses for 5 seconds followed by centrifugation at
14,000 g for 10 min. The protein concentration of the supernatant was
determined according to the BCA protein assay. Protein samples were stored at 20 oC until used for Western blot analysis.

Western blot (WB) analysis. Standard Western blot procedures were performed
as described elsewhere with slight modifications (148, 149). Equal amount of
proteins of contractile and/or synthetic VSMCs were resolved by 7.5 and/or 8.5 %
SDS-PAGE and transferred to polyvinylidene difluoride (PVDF) membranes
using a semidry system. Membranes were blocked with 10 % nonfat dry milk
and/or 5 % BSA in Tris-buffered saline and 0.05 % tween 20 (TBS-T) for 1h at
room temperature (RT). Membranes were then exposed overnight at 4 oC to
primary antibodies against: mouse (ms) anti-α-actin (1:1000), rabbit (rb) antivimentin (1:1000), ms anti-desmin (1:1000), rb anti-KCC1 (1:250), rb anti-KCC4
(1:500), and polyclonal rb anti-APJ (1:1000). Similar protein loading was verified
by probing membranes with ms anti-β-actin (1:1000). PVDF membranes were
then washed extensively in TBS-T and incubated for 2 h with the appropriate
horseradish

peroxidase-conjugated

secondary
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antibodies,

donkey

anti-rb

(1:3000) and/or donkey anti-ms (1:3000) in 10 % nonfat dry milk in TBS-T. Prior
to detection, membranes were washed three times in TBS-T and enhanced
chemiluminescence (ECL) was used for visualization of immunocomplexes using
a high resolution Fuji LAS3000 CCD camera. Band densitometry was performed
by computer software attached to a Kodak camera and/or ImageJ software to
determine the changes in protein expression.

Immunofluorescence. The immunofluorescence procedure was described
elsewhere (137, 138). Here with slight protocol modifications, protein localization
patterns for α-actin, PKG and APJ receptor were determined from contractile
and/or synthetic VSMCs at 25 % confluency. VSMCs were seeded in 8-well
chamber slides (Lab-Tech; NUNC) at a density of 8 x 104 cells/well, washed with
ice cold 1X PBS, fixed with 0.5 mL/well of 4 % paraformaldehyde (± saponin) for
30 min at 4 oC, then incubated in 0.5 mL/well 3 % of normal goat/donkey serum
(NGS/NDS) for 1h at 4 oC to block non-specific immune staining. After serum
removal, cells were incubated with corresponding primary antibodies at the
following concentrations: ms monoclonal anti-α-actin (1:250) in 3 % NGS, rb
polyclonal anti-APJ (1:100) in 3 % NDS and rb anti-PKG (1:100) in 3 % NDS
overnight at 4 oC. Samples incubated with only primary or secondary antibodies
were used to assess specificity of the antibodies used. Cells were then washed
twice with ice cold PBS followed by incubation with anti-ms IgG-FITC (1:1000), or
anti-rb FITC (1:100), or donkey anti-rb Cy3 (1:200) for 1 to 2 h at room
temperature (RT). Finally, cells were washed in cold PBS and with deionized
water. The cells were co-labeled with 4',6-diamidino-2-phenylindole (300 nM
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DAPI) to visualize cell nuclei. Slides were imaged with an inverted Nikon E400
fluorescent microscope using 100X to 400X (oil) magnification and then
superimposed using GIMP software.

Statistical analysis. Graphs were generated using Origin 7.0 (Origin Labs,
Northampton MA) and STATISTIX 7 software (Analytical software, Tallahassee
FL). Most results shown are product of at least two independent experiments with
multiple determinations per condition. Data are reported as mean ± SD or SEM.
Unpaired t-test or One-way ANOVA was performed using Graph pad Prism 5
software (La Jolla, CA). A p value of < 0.05 was considered statistically
significant.
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RESULTS: Specific Aim 1
Growth rate of VSMCs with passage number and according to the
phenotype (contractile and synthetic).
This study utilizes cultured VSMCs as a model system to provide insight into a
better understanding of the differences between VSMCs phenotypes (28).
Several reports correlate VSMCs passage number with their respective
phenotypes. VSMCs at passages 0-4 have been defined as predominantly
contractile, at passage 5 intermediate, and at passages 6 and later as synthetic
(25, 168, 169). Thus, an important factor in characterizing VSMCs properties is
the time for them to proliferate in culture. When seeded at a constant density, an
inverse correlation between time to reach confluence and VSMCs passage
number was observed. For the purpose of comparison, the synthetic VSMCs
populations were grouped based on their passage number: early (6-15); medium
(30-45); and late (70-80). Contractile VSMCs (passages 0-4) required 10-14 days
to reach confluence, whereas, early synthetic phenotype cells achieved
maximum confluence in 4-6 days, and medium and late synthetic phenotype cells
consistently reached confluence in 2-3 days (Figure 15).
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VSMC phenotypic determination by specific markers
The phenotypic transition of VSMCs from contractile to synthetic can be studied
using specific protein markers (e.g., α-actin, myosin, desmin, vimentin,
osteopontin, and others) that are either up- or down-regulated depending upon
the differentiation state of the cells (17-19). Thus, the phenotypic identity of the in
vitro cell populations with antibodies against specific contractile protein markers
was confirmed using SDS-PAGE and Western blotting.
In late synthetic VSMCs phenotype (passage ≥ 70), there was a 60 % reduction
in α-actin (Figure 16A), a 25 % reduction in vimentin (Figure 16B), and a 90 %
reduction in desmin protein expression (Figure 16C). Consistent with the
decrease in α-actin seen in Figure 16, immunofluorescence labeling of α-actin
expression in early and late synthetic VSMCs showed an abundance of
filamentous α-actin in the cytoplasmic compartment of early passage VSMCs
(Figure 17A), whereas in higher passages, α-actin was redistributed or
rearranged in a punctate fashion (Figure 17B).
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Figure 15. Time to reach confluency of vascular smooth muscle cell
(VSMC) cultures as a function of passage number. VSMCs at various
passages (0 – 90) were seeded in T-75 flasks at constant seeding density of 5 x
105 cells/mL per flask. Y-axis shows time (days) to reach confluence in culture
and in the X-axis the passage number. VSMCs at earlier passages (passage 0-4)
were predominantly contractile whereas those at higher passages (≥ 6)
corresponded to increasing populations of synthetic VSMCs.
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Figure 16. Characterization of VSMCs phenotypes in culture with respect
to specific protein markers. Western blots of a representative experiment for
low (L, passage 6), medium (M, passage 38) and high (H, passage 74) passage
VSMCs. Panel A. ~ 43 kDa α-actin. Panel B. ~ 57 kDa vimentin. Panel C. ~ 53
kDa Desmin. Densitometric quantitation of the protein bands shown in A-C were
normalized to β-actin (internal control), and then the quantified protein bands of
M and H passages were normalized to basal expression levels (L as a baseline
control). Densitometry analysis represents mean ± range of two experiments.
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Figure 17. Immunolocalization and distribution of α-actin contractile protein
marker in early and late passage synthetic VSMCs. Immunofluorescence of
FITC-labeled α-actin and DAPI-labeled nuclei in early (Panel A, passage 6) and
late passage (Panel B, passage 89) VSMCs.
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K+ influx pathways in VSMCs
Non-radioactive rubidium (85Rb+) has been used as a potassium congener in
previous ion flux studies (110, 110, 150, 170, 171). In order to isolate the portion
of Rb+ influx that moves through KCC, three Rb+ uptake components were
measured: (1) the total Rb+ uptake in the absence of inhibitors (T), (2) in the
presence of ouabain (oua), and (3) in the presence of ouabain and bumetanide
(oua + bum) as described elsewhere (171). Rb+ uptake through the ouabainsensitive Na+/K+ pump, the ouabain-insensitive and bumetanide-sensitive NKCC,
and [ouabain + bumetanide]-insensitive K+ "leak" component containing the KCC
and K+ channels, were calculated as a function of time. Initial rates for Na +/K+
pump and NKCC were linear up to 5 min. The remaining ouabain- and
bumetanide-insensitive portions of Rb+ influx were linear up to 15 min (Figure
18). In addition, percent Rb+ uptake-mediated by NKCC was higher than
transport via the Na+/K+ pump. Higher transport velocity of NKCC suggests that
in VSMCs, there are more copies of NKCC with higher turnover rate, or they are
mostly activated by phosphorylation. For both the pump and NKCC, the
equilibration was achieved by 20 min (Figure 19).

To study in greater detail KCC in VSMCs, the concentration of ouabain and
bumetanide to block the Na+/K+ pump and NKCC were optimized. First, we
determined the ouabain concentration at which complete inhibition of Rb +
transport via the Na+/K+ pump occurs in VSMCs (Figure 20). In order to achieve
that, Rb+ influx was measured from confluent VSMCs incubated with ouabain
concentrations up to 4 mM. Ouabain was present throughout the whole course of
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the experiment (preincubation and flux; 15 min), or only during flux time period (5
min). Data revealed a 45 % and 65 % reduction in total Rb+ transport when
ouabain concentrations (≥ 2 mM) were present during flux or throughout the
whole course of the experiment. Notably, higher ouabain concentrations were
required to inhibit Na+/K+ pump activity compared to previous reports using
different cell types (eg. Human lens epithelial cells (HLEC), human embroyonic
kidney (HEK-293) cells, etc.) (171, 172). Since the alpha subunit of the Na+/K+
pump is targeted by ouabain, and differences in ouabain sensitivity have been
reported among isoforms (1<2<3); it is possible that alpha 1 isoforms with
low ouabain affinity are highly and predominantly expressed in VSMCs (173,
174).
After determining the optimal ouabain concentration to inhibit the Rb+ mediated
flux via the Na+/K+ pump, similar studies including bumetanide at concentrations
up to 20 M were carried out to further dissect the KCC-mediated Rb+ transport
fraction. As seen in Figure 21, 80 % inhibition of Rb+ transport was obtained
when bumetanide (>1 M) and ouabain (2 mM) were present during
preincubation and flux time periods. In VSMCs, the IC 50 for bumetanide was 0.1
M. Interestingly, bumetanide concentrations in the nanomolar range displayed a
stimulatory effect on Rb+ influx. To date, the mechanisms behind this initial and
transient stimulation of Rb+ transport remains unclear.
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Figure 18. Characterization of Rb+ uptake in VSMCs via various K+
transport pathways. Rb+ uptake (nmoles/mg protein) as a function of time (min)
was tested under isotonic (300 mOsM) conditions. Total Rb + uptake was
measured in the absence of inhibitors (Total, squares), in the presence of
ouabain (1mM) (Oua, circle), and in the presence of ouabain (1 mM) and
bumetanide (10 µM) (Oua + Bum, triangle).

Na+/K+ pump is the difference

between Rb+ uptake in the absence of inhibitors (Total) and in the presence of
ouabain (Oua). NKCC is the difference between Rb + transport in the presence of
ouabain (Oua), and ouabain + bumetanide (Oua + Bum). Finally, KCC and “leak”
mediated by K+ channels is Rb+ transport in the presence of ouabain and
bumetanide (Oua + Bum). Data shown is a representation of three independent
experiments. Data are expressed as mean ± SD (n= 4 per condition).
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Figure 19. Percent Rb+ uptake-mediated via NKCC and Na+/K+ pump in
VSMCs. Rb+ uptakes-mediated by NKCC and Na+/K+ pump were normalized to
that of total uptake in the absence of any inhibitors. NKCC and Na +/K+ pumpmediated uptakes were calculated as described in Material and Methods and
previous section. Normalized Rb+ uptake increased parabolic with time for NKCC
and Na+/K+ pump and equilibrated at 20 min. Data shown is a representative
experiment done in triplicates. For each condition, data reported is mean ± SD (n
= 4 per condition).
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Figure 20. Determination of ouabain concentration optimally inhibiting the
Na+/K+ pump in VSMCs. VSMCs were grown up to confluence and washed
three times with BSS as described in Materials and Methods. The ouabainsensitive flux (OSF) was calculated as the difference between Rb+ influx in the
presence and absence of ouabain and is plotted here as function of ouabain in
flux only (filled squares) or with combination in preincubation and flux (filled
circles). Data fitted with Boltzmann function revealed that ouabain concentrations
≥ 2 mM, when present during flux periods resulted in a 45 % of reduction in Rb +
transport (filled squares). Further inhibition of Rb+ transport (up to 65 %) was
attained when ouabain was present during preincubation and flux periods (filled
circles). Data shown are mean ± SD of a representative experiment done in
triplicates. For each condition, n = 4.
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Figure 21. Bumetanide dose-response curves in rat aortic VSMCs.

Rb+

influx was determined in the presence of ouabain (2 mM) and bumetanide (0-20
µM). With increasing bumetanide concentrations and in the presence of 2 mM
ouabain, NKCC- and Na+/K+ pump- mediated transport mechanisms are
removed and KCC activity can be further dissected. Bumetanide concentrations
above 1 M in combination with 2 mM ouabain resulted in 80 % inhibition of Rb+
influx. The IC50 for bumetanide was found at 0.1 M. Rb+ influx linear between 1
and 20 M bumetanide is the to bumetanide-insensitive (BIS) "leak" pathway
attributed to KCC + K+ channels. Data represents mean ± SD. For each
condition, n = 4.
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Functional characterization of K-Cl cotransport in VSMCs
KCC anion preference (Cl- >Br- >SCN- >I >NO3- >MeSO4-) was previously
established by Lauf and Theg 1980, and Ellory et al 1982 in erythrocytes (84,
121, 175) and later in VSMCs (150). Consistent with previous findings from our
laboratory in VSMCs (149, 150), Figure 22 shows KCC activity, calculated as the
difference of Rb+ uptake in Cl- and Sf-, maintained linearity up to 30 min. To
determine an optimal extracellular [Rb+]o, that would saturate KCC, the activity of
KCC was measured with respect to [Rb+]o and the findings are shown in Figure
23. KCC saturation was achieved at a concentration of 20 mM [Rb +]o. Therefore
in subsequent experiment, [Rb+]o lower than 20 mM within Km value range (10
mM Rb+) were used to assess KCC activity.

Additionally, KCC activity was tested using known stimulators of the system
(hypotonicity and NEM) as shown in Figure 24.

Similar findings have been

previously reported (75, 89, 90, 151, 152) and the effect was reproduced under
the present conditions. KCC activity under hypotonic stimulus was increased by
80 % (with respect to isotonic). The NEM concentration of 0.05 mM has been
used to see the stimulatory effect (90). Our studies showed NEM (0.05 mM)
increased KCC activity by 2-fold. This mode of activation has been a hallmark of
KCC regulation, which suggested that Rb+ influx was indeed mediated by thiol
group modification as originally proposed by Lauf and Theg (84, 176) (Figure
24).
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Figure 22. Rb+ uptake as a function of time was measured under isotonic
condition in Cl- and Sf- media. Rb+ uptake as a function of time was measured
in the presence of Cl- and Sf-, respectively. Ouabain (2 mM) and bumetanide (2
µM) were present during the preincubation and flux. Rb + uptake via KCC was
calculated as the difference in Rb+ uptake in Cl- and Sf-, and was linear up to 30
min. For each time point, n = 4 and values expressed are mean ± standard error.
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Figure 23.
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Figure 23. KCC as a function of varying [Rb+]o. Rb+ uptake was measured in
the presence of increasing concentrations of RbCl between 0 and 40 mM (Panel
A) or RbSf (Panel B) at various time points. The slope “m” of the straight lines
represents the Rb+ influx in Cl- and Sf-. The difference between the slopes
represents the Cl--dependent Rb+ influx (KCC) (Panel C). VSMCs at passage 37
were used for this study. For each time point, n = 4 and the data represent mean
± SD.
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Figure 24. Activation of KCC by hypotonicity and NEM. Percent (%) Cl-dependent Rb+ influx (KCC) was calculated at 5 min in isotonic (control, 300
mOSM), hypotonic (120 mOSM) and in the presence of the thiol-modifying agent
N-ethylmaleimide, NEM (isotonic, 300 mOSM). NEM (final concentration 0.05
mM) was present in the preincubation media as described in Material and
Methods. NaCl was used to increase the osmolality to 300 mOsM. Ouabain (2
mM) and bumetanide (2 µM) were present in both preincubation and flux
solutions to inhibit Na+/K+ pump and NKCC, respectively. For each condition, n =
6, and values are mean ± standard error.
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KCC kinetic parameters in low and high passage synthetic VSMCs
To determine a potential relationship between K-Cl cotransport activity and
VSMCs’ phenotypic transition, we compared the Cl--dependent Rb+ flux in low
and high passage synthetic cells. In order to characterize KCC activity in early
and late passage VSMCs, Rb+ influx was measured as a function of [Rb+]o at
fixed Cl- concentration ([Cl-]o ~ 145 mM) (Figure 25) or as a function of varying
[Cl-]o at fixed [Rb+]o (10 mM) (Figure 26). Both curves show that transport of Rb+
across the cell membrane required presence of both external Cl - and Rb+. At
maximal concentration of these ions, saturation was achieved as described by
the Michaelis-Menten equation. The transport velocity reached a plateau at a
certain substrate concentration and above which there was no substantial
increase in uptake velocity (Figure 25A and Figure 26 A-B). The apparent
binding affinity for Rb+ was higher than that of Cl- (Figure 25B vs Figure 26B).
The maximal rate of Rb+ uptake was similar for both conditions (Figures 25B
and Figure 26B). The Hill coefficient “n” for both ions was close to unity (~ 1)
suggesting there is only one binding site for each ligand. Whether, the binding of
each ligand appears to be independent of a previous or subsequent ligand
binding to the same site, i.e. random order of binding, cannot be determined from
these studies (107, 110).
In low passage VSMCs, similar experiments demonstrated that the Cl -dependent Rb+ transport activity through KCC in the presence of [Rb+]o (10 mM)
or [Cl-]o (145 mM) resulted in a significant 50 % reduction in maximal velocity as
compared to high passage VSMCs (Figure 25D-F, Figure 26D-F and Table 2).
66

The binding affinity (Km) for Rb+ at the external site of KCC was higher than the
apparent binding affinity for Cl- (Figures 25-26 B vs E). The Hill coefficient “n”
was 1 for both Rb+ and Cl- implying presence of one binding site for each ion as
stated earlier (Figures 25-26 B vs E). Table 2 summarizes the average of
several experiments for early and late synthetic VSMCs with respect to the ionic
ligands. As shown in Table 2, the Vmax with respect to external Rb+ and Cl- was
twice for late synthetic, the Km for Rb+ at external KCC binding sites were
consistent in both groups. Apparent affinity for Cl- was higher (low Km value) in
late synthetic VSMCs compared to earlier stages (Table 2).

KCC expression during VSMCs phenotypic switching
During VSMCs’ phenotypic switching, increased motility and proliferation rates
are tightly linked to synthetic states of VSMCs. Additionally, precise control of cell
volume and thus K-Cl cotransport activity is required to allow changes in cell
volume and sustain cell proliferation and motility. With that in mind, we wondered
if changes in KCC protein expression could be associated to VSMCs’
dedifferentiation processes. As can be seen in Figure 27 KCC1 and KCC4 total
protein levels, assessed by Western blot, were increased in later synthetic states.
Interestingly, upregulation of KCC4 seemed to occur earlier compared to KCC1
(Figure 27A vs. Figure 27B). Maximal KCC1 upregulation was observed in
VSMCs cultures at passage 74 (High) whereas KCC4 highest protein levels were
detected at passage 38 (Med). The observed increase in KCC1 and KCC4
expression is in accordance with higher motility and proliferation rates seen in
synthetic VSMCs populations.
67

Figure 25.
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Figure 25. Characterization of KCC kinetics in high passage (P 42) and low
passage (P 8) VSMCs with respect to the external Rb+ concentration. Panels
A-C show kinetics data for high passage and panels D-F are for low passage
VSMCs. (A and D) Cl--dependent Rb+ influx through KCC. KCC activity was
calculated as the difference between the Rb+ influx in Cl- and Sf-. (B and E)
Lineweaver-Burke plot of data in (A and D) to calculate the maximal rate of Rb+
uptake (Vmax) by KCC, and the binding affinity (Km) for Rb+. (C and F) Hill plot
showing the degree of co-operativity “n”. Data shown is a representative
experiment done in quadruplicates. Data calculated is mean ± standard error
(n = 4).
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Figure 26
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Figure 26. Characterization of KCC kinetics in high passage (P 39) VSMCs
and low passage (P 6) with respect to the [Cl-]o. Panels (A-C) are kinetic data
for high passage and panels (D-F) are for low passage VSMCs. (A) KCC activity
was calculated as the difference between the Rb+ influx in Cl- minus Sf- (“Leak”).
KCC saturation was achieved at maximum chloride concentration (145 mM). (B)
Lineweaver-Burke plot showing the apparent binding affinity of the external
binding site of KCC for Cl-, and the maximal rate of Rb+ uptake (Km and Vmax,
respectively). (C) Hill plot showing degree of co-operativity “n”. (D) KCC influx
was decreased compared to high passage VSMCs. (E) Lineweaver-Burke plot
showing apparent binding affinity of Cl- and maximal rate of Rb+ uptake. The Km
was increased (low affinity) as compared to Panel B. The Vmax was decreased by
half as compared to Panel B. (F) Hill plot showing degree of co-operativity “n” =
1, which is similar to high passage VSMCs. The data shown is a representative
experiment with quadruplicate measurements and the values are mean ±
standard error (n=4).
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Table 2. Summary of KCC functional properties in low and high passage
synthetic VSMCs. The maximal velocity, Vm of Rb+ influx was calculated in the
presence of external Rb+ and Cl- (second column). The apparent binding affinity,
Km for Rb+ and Cl- on KCC binding site was calculated from Lineweaver Burk plot
(third column). The Hill coefficients for both Rb+ and Cl- were close to unity ~ 1
(fourth column). Data shown are average of two independent experiments each
done in quadruplicates (n=8) with respect to external Rb + and three independent
experiments each done in quadruplicates (n=12) with respect to external Cl- for
high passage VSMCs.

72

Figure 27. KCC protein expression is increased in late synthetic VSMCs.
VSMCs total extracts from cell cultures at different passage numbers (Low:
passage 6, Med: passage 38, and High: passage 74) were obtained and
separated by SDS-PAGE. Panel A. Normalized KCC1 expression increased in
passage number 74. Panel B. Normalized KCC4 expression was increased in
passage number 38. Densitometric quantitation of the protein bands were
normalized to β-actin (internal control), and then the quantified protein bands of
M and H passages were normalized to basal expression levels (L as a baseline
control). Western blot shown is a representative experiment and densitometry
quantification represents mean ± SD of two experiments for KCC1 and mean ±
SD of three experiments for KCC4.
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DISCUSSION: Specific Aim 1
For long, studying VSMCs’ phenotypic switching has helped to obtain a better
understanding of atherosclerosis progression and occurrence. Here, cultured
VSMCs were used to investigate proliferation rates during their in vitro aging
process. Additionally, we determined differences in cytoskeletal protein marker
expression

that

facilitate

VSMC

phenotypic

identification.

Finally,

K-Cl

cotransport activity, important in cellular homeostasis and for controlling cell
volume and migration, was characterized and optimized conditions for its study
were established.

Due to different gene expression profiles, contractile VSMCs (passages 0-4) are
mostly non-proliferative and thus, replication rates in monolayer cultures are
significantly longer than in synthetic populations (≥ passage 6) (Figure 15) (13,
177). As VSMCs transition to a synthetic state, changes in expression and
reorganization of cytoskeletal proteins are evident (30). Immunofluorescence of
α-actin revealed dramatic changes in expression and subcellular distribution
between contractile and late synthetic VSMCs (Figure 17).

Furthermore,

significant decreases in protein expression levels of α-actin, desmin and vimentin
were observed in late synthetic VSMCs compared to early states. Notably,
desmin total expression was reduced by 90 % in late passage synthetic VSMCs
(Figure

16).

These

results

are

consistent
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with

previous

findings

where expression of cytoskeletal proteins and contractile machinery decreased
during VSMCs’ transition to synthetic states. Similar results have been reported
in blood vessel intimal thickening due to atherosclerotic lesion formation (178,
179).

Initial attempts to characterize the electroneutral K-Cl cotransport in VSMCs
involved the finding and establishment of optimal conditions in which no other
potassium transport mechanism was present. To achieve that, ouabain and
bumetanide dose response curves were performed to allow identification of
conditions at which complete ablation of Na+/K+ pump and NKCC activities could
be obtained. Based on our results, and in accordance with previous reports
showing that rodent Na+/K+ pump is predominantly composed of low ouabain
affinity α1 subunits (O’Brien, WJ et al. 1994; Juhaszova, M. 1997); it is likely that
in VSMCs, α1 subunits are predominantly expressed since higher ouabain
concentrations (up to 2 mM) and longer incubation periods (preincubation and
flux) were required to fully inhibit the Na+/K+ pump.

Additionally, we characterized the K-Cl cotransport in VSMCs with respect to
early and late synthetic phenotypes. K-Cl cotransport activity was assessed with
respect to its known ligands [Rb+ and Cl-]. VSMCs of late synthetic passage had
different transport activities and apparent affinities for Cl- as compared to early
synthetic VSMCs (Figures 25-26, and Table 2). Rb+ transport via KCC required
simultaneous presence of both Cl- and Rb+ ions externally. The maximal
transport velocity of Rb+ (Vmax) increased by 2-fold in late synthetic cells. Whether
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this increase is due to turnover changes of pre-existing KCCs or enhanced
membrane trafficking/insertion of de novo synthesized KCC proteins, remains to
be studied. In late synthetic VSMCs, the apparent affinity for Cl - increased, while
the affinity for Rb+ remained fairly constant. It is possible that conformational
changes due to KCC isoform assembly or posttranslational modifications might
be responsible for increased Cl- affinity.

Interestingly, in both early and late

synthetic VSMCs, KCC activity showed an obligatory coupled movement of Rb +
and Cl- in 1:1 stoichiometry ratio, as suggested by Hill coefficient of 1. This
observation indicates that this mode of cotransport is electroneutral, and is in
agreement with previously reported models (87, 180, 181). Whether, the binding
of each ligand appears to be independent of a previous or subsequent ligand
binding to the same site, i.e. random order of binding, cannot be determined from
these studies (107, 110).

Shedding light onto K-Cl cotransport regulation is of considerable importance
since several lines of evidence have highlighted KCC activity in sustaining
human health and during the occurrence of pathophysiological conditions (75,
133, 137, 145, 158, 160, 181). Stimulation of K-Cl cotransport activity during
hypotonicity and NEM treatment, constitute original hallmarks of this mode of
electroneutral ionic transport. Consistent with previous findings, hypotonicity and
NEM treatment resulted in significant stimulation of K-Cl cotransport. Therefore, it
is likely that common signaling pathways and regulatory mechanisms are
conserved among cell types (Figure 20) (84, 122, 180, 182-184). Previous
studies have suggested that during both, hypotonicity- and NEM-treatment; KCC
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upregulation is due to dephosphorylation of key serine and threonine residues
within its C-terminus. It is likely that inhibition of kinase activities such as WNK
and Ste20, in combination with activation of protein phosphatases like PP1/2,
results in concomitant KCC de-phosphorylation and thus activation (185-187).

Changes in KCC activities observed in Figures 25 and 26 could be explained by
re-distribution of cytoskeletal proteins that would promote their trafficking to the
cell membrane and recruitment of regulatory proteins (91). As cytoskeletal
proteins regulate intracellular signaling cascades their distribution and location
may be important for determining VSMC phenotype. Thus, any reorganization of
the cytoskeleton or signaling molecules could affect VSMCs phenotypic
modulation (30). Moreover, several cell culture models suggest that the
cytoskeleton machinery is linked to cell migration (91, 188, 189). Further
evidence also indicates emerging roles of ion channels and transporters playing
a significant role in cell migration (163, 190, 191). During the cell migratory
process, there is polarized distribution of ion channels or transporters due to
structural reorganization of the cytoskeleton. Based on our findings, it is plausible
that as VSMCs undergo phenotypic transformation; decreased interaction
between KCC and cytoskeletal proteins could enhance membrane trafficking and
increases in transport activity (137).
We also demonstrated that during VSMCs dedifferentiation or phenotypic
switching, KCC1 and KCC4 expression is increased. These results further
support the notion that high levels of K-Cl cotransport activity are necessary to
attain a better control of cell volume and proliferation/migration processes.
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Importantly, our results suggest that up regulation of different KCC isoforms
could be passage number-dependent. It remains to be determined whether
changes in expression of other KCC isoforms (KCC2 and KCC3) occur during
the studied conditions. Since KCC1 up regulation occurred at later states
(passage 74), in which KCC4 protein levels were comparable to the ones seen at
passage number 6; it is possible that mutually exclusive gene-expression profiles
occur in VSMCs. In sum, at late VSMCs’ passage numbers, K-Cl cotransport
activity is enhanced by both, and increase in enzyme kinetics (ion affinity and
Vmax) and KCC protein levels.

It is possible that the numbers of KCCs transporters do not change in the plasma
membrane or that new KCCs are synthetized as cells undergo cell division.
Furthermore, kinases could be involved in KCC regulation and change their
expression pattern. In addition, it is likely that expression patterns are changing
and those changes are responsible of the overall observation. Our data also
showed that the transition of the VSMCs phenotype is linked to the expression
and activity of KCC. Likewise, KCC regulation could lead to a VSMCs phenotypic
transition with enhanced migration and proliferation. Recent studies have
correlated

the

expression

of

KCC

isoforms

in

embryogenesis

and

dedifferentiated cancerous cells linking KCC to tumorigenesis, cell proliferation,
and migration (133, 134, 158-160). Similarly, VSMCs synthetic phenotypic
transition is also linked to cell proliferation and migration (192). Thus, KCC
activity and expression could be an important modulator of VSMCs transiting to
synthetic phenotypes.
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SUMMARY
The main finding of this study is that concomitant with the process of VSMCs’
transition from early to late synthetic phenotype, there is an increase in KCC
functional properties. Additionally, KCC1 and KCC4 protein levels were upregulated, whereas considerable reductions of cytoskeletal proteins were found.
Altogether our results suggest a link between KCC activity/expression and
VSMC’s phenotypic switching.
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SPECIFIC AIM 2

To determine the acute and chronic effect of apelin on K-Cl cotransport
activity in VSMCs. To establish the involvement of NO, PI3K/Akt and MAPK
signaling pathways in the regulation of the transporter.
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RESULTS: Specific Aim 2
Apelin receptor is expressed in VSMCs
To establish whether the most abundant and potent form of apelin (apelin-13)
might affect K-Cl cotransport via its membrane receptor APJ (predicted MW
42.35 kDa), western blot analyses using total lysates from contractile and
synthetic VSMCs were performed using the validated commercial antibody
against APJ (Figure 28A). Since APJ protein expression has been previously
reported and extensively studied in central nervous system, brain extracts were
used as control for APJ immunodetection (52, 193). As shown in Figure 28A,
differences in APJ protein expression were observed between brain samples and
among VSMC phenotypes (contractile vs synthetic). First, there was a difference
in size of APJ compared to predicted molecular weight between brain (~55 kDa)
and VSMCs (~60 kDa). These differences in APJ molecular size suggest
possible tissue-specific post-translational modifications/processing that would
require further detailed examination. Second, in contrast to brain samples, strong
APJ bands were detected from VSMCs samples at around 120 kDa indicating
either nonspecific antibody binding or possible APJ oligomerization. Lastly,
densitometric analysis of total APJ (monomeric and dimeric) normalized to bactin, revealed a decreasing trend in APJ protein expression corresponding to
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VSMCs’ phenotypic states. Total extracts of late synthetic VSMCs (passage
number 41) revealed a possible reduction (30 %) in APJ expression compared
to contractile or early synthetic VSMCs (passage numbers 2 and 9 respectively)
(Figure 28B). In addition, APJ immunolabeling revealed differences in its
subcellular localization among VSMCs’ phenotypes. In synthetic VSMCs
(passage number 17), the majority of APJ expression was homogeneously
distributed along the cytoplasm (Figure 28C), whereas a more localized
perinuclear immunolabelling pattern was detected in contractile states (passage
number 2) (Figure 28D). These observed differences in protein expression
levels, oligomerization and subcellular localization of APJ could result in
variability of the apelin-mediated effects in different VSMCs’ phenotypes. To
confirm primary antibody specificity, VSMCs were incubated in its absence
(Figure 28C and D).
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Figure 28. APJ protein expression. (A) Protein extracts (40 g/lane) from brain
and VSMCs primary cultures (synthetic and contractile) were separated by SDSPAGE and subsequent immuno-detection of APJ was performed. APJ monomer
conformation was detectable around 60 kDa. Interestingly, the APJ signal from
VSMCs was slightly different in size when compared to brain total protein extract.
Strong immuno-detection at 120 kDa was detected in VSMCs protein extracts as
well as weakly in brain tissue suggesting SDS resistant oligomerization. Anti-APJ
primary antibody (1:1000) and -actin (1:2000) was used as an internal control.
(B) Densitometric analysis of total APJ (monomeric and dimeric) relative to actin in VSMCs from a representative experiment. (C) Immuno-labeling of APJ in
synthetic VSMCs. (D) Immunolabeling of APJ in contractile VSMCs. In both
cases, VSMCs were fixed, permeabilized, and incubated with anti-APJ antibody
(1:100); (FITC)-conjugated secondary antibody was used against anti-APJ
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(1:100). As a negative control; synthetic (C) and contractile (D) VSMCs were
incubated with a 3% normal goat serum (NGS) and (FITC)-conjugated secondary
antibody (1:100).

84

Once evidence was gathered suggesting APJ protein expression in VSMCs, we
determined the timeframe in which apelin-13 treatment would act upon the linear
behavior on K-Cl cotransport activity. Cl--dependent Rb+ uptake from untreated
and apelin-treated VSMCs was assessed from 0 to 40 min. K-Cl cotransport from
1 µM apelin-treated VSMCs, was linear up to 40 min (Figure 29). Thus,
subsequent determinations of K-Cl cotransport activity were performed within the
aforementioned timeframe.

Acute apelin regulation of K-Cl cotransport in serum-starved VSMCs
Apelin regulation of K-Cl cotransport by the NO-mediated signaling
pathway and the role of oxLDL
Previous studies have shown that the guanyl cyclase PKG is one of the most
important regulators of K-Cl cotransport and determinant of VSMCs contractile
phenotype (22, 103, 148). In order to establish a direct link between the apelin
effect and the NO-mediated regulation of KCC, immuno-labeling of PKG was
performed in contractile VSMCs. As can be seen in Figure 30A, clear immunodetection of PKG was observed. Primary antibody specificity was determined in
the absence of PKG antibody (Figure 30). All slides were counterstained with
4′,6-diamidino-2-phenylindole (DAPI) to visualize cell nuclei (Figures 28C-D and
30B).
To further assess whether apelin regulates K-Cl cotransport through the
NO/cGMP/PKG pathway, VSMCs were used at < passage 4, when they are in
the contractile state, to ensure PKG is present. VSMCs were cultured until sub
confluence and then serum deprived for 24 h prior to flux measurement. Cells
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were then incubated with 2.5 µM KT5823, a potent inhibitor of PKG for 10 min in
preincubation media followed by additional 30 min during flux in the presence
and absence of apelin (1 µM). The experimental outcomes of each condition
were normalized relative to the control. As shown in Figure 31A, the inhibitor
alone did not affect the basal K-Cl cotransport activity. Apelin treatment of serumstarved contractile (PKG positive) VSMCs resulted in a significant increase of
87.3 % (*p < 0.05) compared to the basal K-Cl cotransport activity. Importantly,
when contractile VSMCs were incubated in the presence of KT5823, the apelinmediated increase in K-Cl cotransport was prevented suggesting that apelin uses
NO pathway to regulate K-Cl cotransport activity.

Because oxLDL modulate progression of atherosclerosis by impairing the NOmediated pathway in contractile VSMCs (194, 195), we tested whether oxLDL
might affect K-Cl cotransport activity, which was shown to be modulated by
apelin. Rb+ influx was measured in contractile VSMCs (passage 4) treated for 24
h ± 8 μg/mL oxLDL and then followed by a 40 min incubation of 4 μM apelin. Cl-dependent Rb+ influx for each condition were normalized to the baseline control.
Apelin treatment resulted in an increase in K-Cl cotransport by 2-fold (* p < 0.05);
whereas the baseline KCC was inhibited significantly by oxLDL by over 70 % (* p
< 0.05). The oxLDL-mediated inhibition of KCCs was restored by apelin
treatment and importantly, similar fold of apelin-mediated activation was obtained
from untreated VSMCs (Figure 31B). This suggests that oxLDL and apelin have
a counter-regulatory action in the regulation of K-Cl cotransport activity in
VSMCs.
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Figure 29. Cl--dependent Rb+ uptake as a function of time in the presence
of apelin. Cl--dependent Rb+ uptake was measured as a function of time from
24 h-serum deprived VSMCs. Untreated VSMCs: (filled squares). VSMCs treated
with 1 µM apelin for 40 min incubation time (open circles). Rb + uptake was
measured in the presence of ouabain (2 mM) and bumetanide (2 µM) for 10-40
min at 37 oC. For each conditions, n = 4 and values are reported as mean ± SD.
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Figure 30. Immunolabeling of PKG in contractile VSMCs. Contractile VSMCs
(passage 3) were fixed, permeabilized and incubated with anti-PKG 1 antibody.
Cy3-conjugated secondary antibody was used against anti-PKG 1. In negative
control VSMCs were incubated with a 3 % normal goat serum (NGS) and Cy3conjugated secondary antibody.

88

Figure 31.
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Figure 31. Apelin effect on K-Cl cotransport by the NO-mediated pathway.
(A) KCC-mediated Rb+ uptake from 24 h-serum deprived contractile VSMCs was
measured in the presence or absence of 1 µM apelin and 2.5 µM of KT5823, an
inhibitor of PKG. The experimental outcomes were normalized relative to the
baseline control. Data represent means ± standard errors of two independent
experiments each done in triplicates, n = 6 per conditions. *p<0.05 vs control
group. (B) Apelin rescues oxLDL-mediated inhibition of KCC activity. KCCmediated Rb+ uptake, from 24h-serum deprived contractile VSMCs, was
measured in the presence or absence of 4 μM apelin and 8 μg/mL oxLDL.
Subconfluent cells were incubated oxLDL in serum free media for 24 h. Cells
were then washed with BSS and Rb+ influx assay was carried out as described in
Materials and Methods. Apelin was added during flux to see an acute effect on
oxLDL-treated cells. Data represents mean ± standard error, n = 3 per
conditions. *p<0.05 vs control group.
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Apelin regulation of K-Cl cotransport by PI3K/Akt and MAPK-mediated
signaling pathways
VSMCs motility and proliferation have been tightly linked to the activation of
PI3K/Akt and MAPK signaling pathways that are important for vascular
remodeling and repair. Similarly, apelin effects on motility involve stimulation of
the aforementioned signaling cascades. Therefore, we assessed the effect of
selective inhibitors of the PI3K/Akt and MAPK pathways on K-Cl cotransport
activity in the presence or absence of apelin. Sub confluent synthetic VSMCs
(passages 6-8) were serum starved for 24 h prior to flux measurement. Cells
were then incubated for 10 min with 10 µM of either LY294002 or PD98059,
selective inhibitors of PI3K/Akt and ERK1/2, respectively. Then cells were further
incubated with these inhibitors for additional 40 min during flux in the presence or
absence of apelin. The outcomes of each experimental condition were
normalized to the baseline control. As can be seen in Figure 32A and 32B,
acute apelin treatment resulted in activation of K-Cl cotransport in synthetic
VSMCs by 142% (*p < 0.05). Baseline activity was not affected by neither of the
inhibitors used. However, VSMCs incubated with the inhibitors were no longer
responsive to apelin-mediated activation of K-Cl cotransport activity. These
results point out apelin/APJ regulates KCC via PI3K/Akt and MAPK pathways. A
summary of the signaling pathways that result in K-Cl cotransport upregulation by
apelin and the usage of selective inhibitors are displayed in Figure 33. Inhibitors,
KT5823, PD98059 and LY294002 blocked the activation of K-Cl cotransport in
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the presence of apelin. OxLDL inhibitory effect on K-Cl cotransport activity was
rescued to the baseline levels by apelin (Figure 33).
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Figure 32.
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Figure 32. Apelin-mediated activation of KCC occurs through a PI3K/Akt
and MAPK pathways in synthetic VSMCs. (A) Apelin-mediated activation of
KCC occurs through the PI3K/Akt pathway. KCC-mediated Rb+ uptake by 24 hserum deprived synthetic VSMCs was measured, according to Materials and
Methods, in the presence or absence of 1 µM apelin and 10 µM of LY294002, an
inhibitor of the PI3K/Akt pathway. LY294002 was present in preincubation and
flux media. Apelin was added to flux solution. (B) Apelin-mediated activation of
KCC occurs through a MAPK dependent pathway in synthetic VSMC. KCCmediated Rb+ uptake by 24h-serum-deprived synthetic VSMCs was measured in
the presence or absence of 1 µM apelin and 10 µM of PD98059, an inhibitor of
the MAPK pathway, in preincubation and flux. For both (A) and (B), experimental
outcomes were normalized to the baseline control. Data represents mean ±
standard error of two independent experiments done in triplicates. For each
conditions, n = 6. *p<0.05 vs control group.
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Figure 33. Proposed signal transduction pathway of K-Cl cotransport
regulation by apelin in contractile and synthetic VSMCs. Apelin binds to its
receptor APJ and elicits three signaling pathways. Whereas oxLDL inhibits K-Cl
cotransport activity, in contractile VSMCs, apelin uses the NO-mediated pathway
to sustain this mode of cotransport. In synthetic VSMCs, apelin uses the
PI3K/Akt and MAPK-mediated pathways to activate K-Cl cotransport activity. The
drugs KT5823, LY294002 and PD98059 block the NO, PI3K/Akt and MAPK
pathways, respectively.
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Chronic treatment with apelin does not change K-Cl cotransport activity in
serum-starved VSMCs
Once we showed that acute treatment of apelin resulted in stimulation of K-Cl
cotransport activity, we wondered if longer incubation times had the same effect.
To this end, apelin was added to growth media before the flux time periods. As
can be seen in Figure 34, serum-starved VSMCs were treated with 1 µM apelin
for: 30 min, 1 h, 6 h, 12 h, 18 h or 24 h. Cells were rinsed thoroughly with BSS
and K-Cl cotransport was compared to untreated cells (see Materials and
Methods). As shown in Figure 34, no significance change in Rb+ flux was
observed between untreated and apelin-treated VSMCs. To rule out the
possibility that lack of effect on KCC activity was due to apelin degradation,
MALDI-TOF mass spectrometry analyses were carried out with the assistance of
Dr. David Cool. After apelin reconstitution in deionized water at 50 microgram
final stock concentration, and over one year of storage, no evidence for
proteolysis was detectable. As seen in Figure 35, three peaks at monoisotropic
mass of 1532, 1555 and 1578 corresponding to apelin and sodium adducts
confirmed the apelin integrity in solution.
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Figure 34. Time-course of chronic apelin incubation on K-Cl cotransport.
Cells serum-deprived for 24 h were exposed to 1µM apelin during different time
periods. After termination of apelin incubation, cells were washed 3 times with
BSS solution and the flux experiment was carried out as described in Materials
and Methods. Apelin was not present during the flux time. Ouabain (2 mM) and
bumetanide (2 µM) were present during both the preincubation and flux. After 10
min of Rb+ flux, no difference in KCC activity was observed between untreated
(filled squares) and apelin-treated VSMCs (filled circles). Data shown is mean ±
standard error of a representative experiment done in triplicates. For each
condition, n = 3.
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Figure 35.
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Figure 35. Mass spectrometry of water reconstituted apelin.

Apelin, 50

micrograms, was mixed 1:1 with CHCA matrix and 1 microliter was spotted to a
MALDI brushed steel plate. A Bruker Autoflex III MALDI-TOF was used to
capture the data with laser intensity settings adjusted at 70%, gain to 4.0 and
3000 laser shots captured randomly around the spot. The data represent the
expected mass of apelin at 1532 Da, and sodium adducts at 1555 and 1578 Da.
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SPECIFIC AIM 3

To assess the factors, such as, serum, osmolality, ionic strength, VSMCs
phenotypes on apelin-mediated effect on K-Cl cotransport activity. The
above factors will shed light on possible variability of the response of K-Cl
activity to apelin.
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RESULTS: Specific Aim 3
Factors affecting apelin response: Variable effects on K-Cl cotransport
activity.
During the determination of K-Cl cotransport activity, variability in the extent of
activation after apelin treatment became evident. Being aware of several factors,
such as the effect of serum deprivation, extracellular ionic content and
osmolalities as determinants for changes in K-Cl cotransport, we determined
whether serum deprivation and/or sodium-free media altered the apelin-mediated
Rb+ response in VSMCs (150, 182).
As shown in Figure 36 (A and B), the absence of extracellular Na+ prevented the
apelin-mediated increase in K-Cl cotransport activity irrespective of serum
deprivation, cell phenotype (synthetic and contractile) and extracellular
osmolality. In addition, neither hypotonic incubation (known to activate K-Cl
cotransport) nor apelin treatment resulted in changes in Rb + influx levels under
these conditions. Furthermore, previously described inhibitory stimuli, such as,
hypertonicity resulted in no change in K-Cl cotransport activity and similarly,
apelin treatment had no effect in Rb+ influx. To date, the role of extracelluar Na+
in sustaining KCC activity and regulation remains unclear.

To further dissect the variability behind the apelin-mediated effect on K-Cl
cotransport, the effect of extracellular Na+ on serum-deprived and serum-fed
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synthetic VSMCs was tested. As shown in Figure 37, the addition of external
Na+ did not sustain the previously shown apelin-mediated increase of Rb+ influx.
In contrast, the combination of serum and extracellular Na + allowed apelin to
potentiate the K-Cl cotransport under hypotonicity and hypertonicity. Surprisingly,
under isotonic conditions, apelin treatment did not result in changes of baseline
Rb+ influx (Figure 37B).

102

Figure 36.
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Figure 36. Effect of apelin on KCC activity in primary cultures of rat aortic
vascular smooth muscle cells (VSMCs) with respect to various osmolalities
in the absence of Na+ and serum. Panel (A) Synthetic VSMCs (passage 39),
and Panel (B) Contractile VSMCs (passage 3). Rb+ influx was determined from
serum-starved cells at different osmolalities in Na+-free solutions. Osmolality
changes were achieved by adding NMDGCl and NMDGSf. Ouabain (2 mM) and
bumetanide (2 µM) were present in preincubation and flux solution. Apelin (1 µM)
was added during flux. The difference between Rb + influx in NMDGCl and
NMDGSf was used to determine Na+-independent KCC activity. Data represents
mean ± standard error and for each condition n = 6.

104

Figure 37.
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Figure 37. Effect of apelin on KCC activity with respect to various
osmolalities in serum-starved and serum-fed VSMCs in the presence of
external Na+. KCC activity was measured from serum-starved and serum-fed
(24 h) VSMCs (passage 11) in the presence of external Na + at different
osmolalities (Panel A and B). NaCl and NaSf were used to increase the
osmolality. Cells were exposed to various tonicities in the preincubation and flux
media containing ouabain (2 mM) and bumetanide (5 µM). Apelin (1 µM) was
added during flux. As shown in Panel (A) apelin treatment did not change KCC
activity in serum-starved cells. In Panel (B) apelin treatment significantly
increased KCC activity under hypo and hypertonicity. Data shown are mean ±
standard error with n = 3 per conditions. *p < 0.05 vs control group.
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Since incomplete inhibition of alternative K+/Rb+ transport mechanisms such as,
the ouabain-sensitive Na+/K+ pump and/or bumetanide-sensitive Na+-K+-2Clcotransporter could be responsible for the apparent lack of apelin effect under
isotonic conditions, we performed dose-response curves to rule out the possibility
of residual Rb+ transport with ouabain (2 mM) and bumetanide (2-5 µM)
concentrations used so far. As shown in Figure 38, ouabain (2 mM) resulted in
complete inhibition of the Na+/K+ pump. Addition of ouabain to the preincubation
media did not result in any further inhibition of the ouabain-sensitive Rb+
transport compared to the one observed during flux incubation period. As seen in
Figures 39A-C, residual K+/Rb+ transport was detectable at 2 µM bumetanide.
Therefore, higher bumetanide concentrations (up to 30 µM) will be required to
fully

inhibit

Na+-K+-2Cl-

cotransport

activity

in

subsequent

Rb+

influx

determinations.
Having determined the requirement of extracellular Na+ and presence of serum in
the growth media for the apelin-mediated increase in K-Cl cotransport, we
reevaluated the osmolality-dependency of Rb+ fluxes in VSMCs using 30 µM
bumetanide (Figure 40). To our surprise, extracellular Na+ was required for K-Cl
cotransport to be activated and inhibited under hypotonicity and hypertonicity,
respectively (Figure 40A). Presence of extracellular Na+ and serum in the growth
media resulted in activation and inhibition of K-Cl cotransport under hypo- and
hypertonic conditions, respectively (Figure 40B). Simultaneous K-Cl cotransport
inhibition and activation of Na+-K+-2Cl- mechanisms during increases in
osmolality confirmed the physiological relevance of regulatory volume responses
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necessary to properly control cell volume (Figure 41). To further confirm the
coordinated activity of K+ transport mechanisms (K-Cl cotransport vs. Na+-K+-2Cl); Na+-K+-2Cl- activity was assessed under the same conditions. As shown in
Figure 41A, whereas increases in osmolality inhibited K-Cl cotransport, opposite
regulation (activation) of Na+-K+-2Cl- was observed (Figure 41B). In other words,
presence of extracellular Na+ and serum in the growth media resulted in the
expected activation of K-Cl and possibly inhibition of Na+-K+-2Cl- (Figure 41A
and B). These results highlight the coordinate activity of cation chloride
cotransporters (CCCs) to modulate intracellular Cl- concentration and therefore
cell volume.
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Figure 38. Ouabain dose-reponse curve. KCC activity was measured in
isotonic condition in the presence of increasing concentration of ouabain ranging
from 0-2 mM and in the presence of 5 µM bumetanide to inhibit Na +-K+-2Clcotransporter. Cl--dependent Rb+ influx (KCC) became stable by 2 mM ouabain
and there was no difference in KCC activity when ouabain was present in flux
(filled black squares) vs. preincubation and flux (filled red circles) at highest
concentration used. Data represents mean ± standard error of a representative
experiment with n = 3 per condition.
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Figure 39. Bumetanide dose-response with respect to various osmolalities.
Panel (A) Hypotonic conditions, Panel (B) Isotonic condition, and Panel (C)
Hypertonic condition. NaCl and NaSf salts were used to increase the tonicity of
external media. Confluent VSMCs were washed three times with BSS and flux
experiment was carried out as described in Materials and Methods. Cl-dependent Rb+ influx, KCC, activity was assessed in the presence of bumetanide
concentration ranging from 0-50 µM (present during preincubation + flux).
Ouabain (2 mM) was present to inhibit the Na+/K+ pump. Flux was performed at 5
min and 20 min time period. The Rb+ influx in Cl- was subtracted from that in Sfmedia to yield the Cl--dependent Rb+ influx. Data represent mean ± error of three
independent experiments with n = 3 per conditions.
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Figure 40.
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Figure 40. External Na+ influences KCC sensitivity to osmoregulation.
Serum-fed VSMCs were fluxed in the absence (Panel A) or presence (Panel B)
of external Na+ at different osmolalities. Changes in osmolality from solutions
containing Na+ were achieved by using NaCl and NaSf, whereas NMDGCl and
NMDGSf were used for Na+-free media. Ouabain (2 mM) and bumetanide (30
µM) was used to inhibit Na+/K+ pump and Na+-K+-2Cl+. As shown in Panel B,
KCC activity is differentially regulated according to changes in osmolality. In
contrast, in Na+-free media (Panel A), KCC activity was unresponsive to changes
in osmolality. Data represents mean ± standard error of a representative
experiment with n = 3 per condition.
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Figure 41.
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Figure 41. NKCC and KCC activation tightly and reciprocally regulated
(Yin-Yang mechanism). To establish Yin-Yang canonical mechanism between
NKCC and KCC along different tonicities (NaCl and NaSf were used to increase
the tonicity of external media). VSMCs were grown in serum enriched media until
subconfluency and Rb+ influx was tested in the presence of external Na +, and
ouabain (2 mM) and bumetanide (30 µM) was used in preincubation and flux.
Data represents mean ± standard error of three experiments with n = 3 per
condition.
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Apelin effect on K-Cl cotransport in serum-fed VSMCs under different
osmolalities.
To further dissect the mechanism(s) behind the apelin-mediated increase in K-Cl
cotransport, we treated subconfluent serum-fed VSMCs with apelin at different
osmolalites by either modifying the ionic strength or keeping it constant (addition
of sucrose). In previous Figures 29 to 37A, VSMCs were serum deprived for 24
h before being exposed to apelin. This time, Rb+ influx was measured in apelintreated VSMCs that were grown in serum containing media. Under constant ionic
strength where sucrose was used to increase the extracellular osmolalities, the
apelin response was not detectable (Figure 42). Thus, subsequent experiments
were conducted under variable ionic strength conditions which resemble
physiological challenges in vivo. To shed light into the mechanism(s) behind the
lack of apelin effect under isotonic condition tested under 5 µM bumetanide
(Figure 37B), 30 µM bumetanide was used on contractile VSMCs at different
osmolalities obtained by modifying ionic strength. As shown in Figure 43, apelin
treatment allowed increases in K-Cl cotransport in hypo- and hypertonic
conditions. Interestingly, the extent of activation was considerably less when
compared to synthetic VSMCs (Figure 37B vs 43). These results suggest that
heterogeneous cultures of synthetic VSMCs might be unresponsive to apelin
when cell integrity is not compromised by changes in osmolality (isotonic
conditions). When similar assays were carried out using contractile VSMCs
(Figure 43) a major difference in the apelin-mediated effect was observed. Under
isotonic conditions, K-Cl cotransport activity in serum-fed contractile VSMCs was
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stimulated by apelin treatment. Altogether these results suggest that contractile
VSMCs under isotonic conditions might be more susceptible to apelin effects.
These findings are in accordance with a more pronounced need in the
responsiveness to apelin from contractile/healthy VSMCs to aid in the repair of
damaged endothelium.
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Figure 42. Effect of apelin in constant ionic strength. In serum-fed contractile
(Panel A) and synthetic (Panel B) cells, KCC activity was measured in the
presence or absence of apelin at different osmolalities. Sucrose was used to
change the osmolality of the flux solution while keeping the concentration of other
salts constant. As can be seen, apelin treatment did not change KCC activity
under this condition. Data represents mean ± standard error of two independent
experiments done in triplicates (n = 6).
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Figure 43. Effect of apelin on KCC activity in serum-fed contractile cells
with respect to increase in external osmolality. Contractile VSMCs (passage
3) were grown in serum enriched media until subconfluency. Cells were then
washed and exposed to different osmolalities (Hypotonic: 120 mOSM, Isotonic:
300 mOSM and Hypertonic: 450 mOSM) in the preincubation and flux media
containing ouabain (2 mM) and bumetanide (30 µM). NaCl and NaSf salts were
used to change the osmolalities of the external media. For each condition, n = 3
and the values are mean ± standard error. *p < 0.05 vs control group.
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Apelin effect on K-Cl cotransport activity in synthetic VSMCs at different
time point under hypotonic conditions
We then evaluated the kinetics of the effect of apelin in hypotonic conditions on
K-Cl cotransport activity. VSMCs were grown until subconfluency in serum rich
media and then apelin was added for 30 minutes, 1 hour, 12 hours, 18 hours and
24 hours before flux.

Cells were then exposed to hypotonic media and Cl --

dependent Rb+ influx was measured for 20 min in the presence of 1 µM apelin.
As shown in Figure 44; apelin treatment resulted in significant increases on K-Cl
cotransport at most time points tested. Interestingly, after 24 h of 1 µM apelin
incubation; no significant increase in K-Cl cotransport was detected. It is possible
that long exposure times result in APJ desensitization (internalization) and
therefore absence of apelin effect on K-Cl cotransport activity. GPCRs like APJ
can be desensitized following activation by agonists through phosphorylation by
members of the GRKs (G-protein coupled receptor kinases (196). This mode of
control of APJ remains to be further studied.
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Figure 44. Effect of apelin in hypotonic conditions at different time points.
Subconfluent VSMCs were incubated in the presence of 1 µM apelin for 30 min,
1 hour, 12 hours, 18 hours and 24 hours in a serum enriched growth media. Cells
were then washed with BSS solution and flux measurement was carried out
under hypotonic conditions in the presence of Ouabain (2 mM) and bumetanide
(30 µM) to inhibit the pump and Na+-K+-2Cl- cotransport activity as described in
MATERIALS AND METHODS. Apelin was added for additional 20 min during flux
to the treatment groups. Each experimental outcome was normalized to its
control. Apelin treatment resulted in significant increases of K-Cl cotransport
activity in all time points tested except 24 hours. It is possible that APJ
desensitization at 24 h could be the reason of absence of apelin stimulatory
effect. Data represents mean ± standard error (n = 3 per conditions). *p < 0.05 vs
control group.
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Apelin regulatory effect on K-Cl cotransport activity during changes in
osmolality in serum-fed synthetic phenotypes
VSMCs of synthetic passages are implicated in atherosclerosis. Thus, to assess
apelin-induced K-Cl cotransport activity, VSMCs of various synthetic passages
were examined. Urged by the observation that K-Cl cotransport could still be
stimulated by apelin under hypertonic conditions (in which basal KCC activity is
normally abrogated) (Figure 37B and 43) (91, 111), we examined whether
manipulation of cell volume by shrinking and swelling could result in differences
in the apelin response. Although we did not measure cell volume in our study, we
did modulate external osmolality which would produce similar changes in cellular
volume. Figure 45 shows various conditions where apelin effects were tested
during: a) cell swelling (hypotonicity), b) shrinkage (hypertonicity), c) shrinkage
followed by swelling or d) swelling followed by shrinkage.

As can be seen in Figure 45A, under hypotonic conditions/cell swelling, apelin
treatment further enhanced the activation of K-Cl cotransport by 54 % (*p < 0.05).
Importantly, osmolarity shifts from hypertonicity to hypotonicity (shrinkage
followed by swelling) did not affect the apelin stimulatory effect (74 % increase,
**p < 0.01) on KCC activity. These findings strongly suggest that apelin might
potentiate regulatory volume decrease (RVD) mechanisms. When preswollen
VSMCs were shrunken by shifting them from hypotonicity to hypertonicity
(swelling followed by shrinkage); apelin treatment failed to stimulate KCC activity
(Figure 45B). Next we established whether VSMCs’ progression to late synthetic
states affected the apelin stimulatory effect in KCC activity during a shift from
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hypertonicity to hypotonicity. As shown in Figure 46A, the apelin stimulatory
effect was stronger in early synthetic VSMCs (passage number 7) when
compared to later states (passage number 13 and 20). Similarly, and in
accordance with Figure 45B; when pre-swollen VSMCs from different passage
numbers were shifted to hypertonicity, apelin treatment failed to promote K-Cl
cotransport (Figure 46B). The summaries of apelin response from contractile
and synthetic VSMCs with respect to various factors are displayed in Table 3.
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Figure 45.
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Figure 45. Apelin enhances KCC sensitivity with changes in external
osmolality. KCC-mediated Rb+ influx was measured in synthetic serum-fed
VSMCs (passage 7). Cells were grown in serum enriched media and after
reaching sub confluence, apelin was added for 6 h in the treatment group. Apelin
was added for additional 20 min during flux; whereas, the control group
contained no apelin. Panel (A). Apelin stimulated KCC activity in hypotonic
condition (120 mOSM) and also in preshrunken cells that were first exposed to
hypertonic solution (450 mOSM) during preincubation (10 min) and then in
hypotonic solution (120 mOSM) during flux (20 min). Panel (B) Apelin stimulated
KCC activity (borderline significant) under hypertonic conditions (450 mOSM) but
lack of apelin response was observed in pre-swollen cells when the cells were
transferred from hypotonic (120 mOSM) to hypertonic conditions (450 mOSM).
Data represents mean ± standard error (n = 6 per conditions). *p < 0.05 vs
control group.
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Figure 46.
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Figure 46. Apelin response in preshrunken cells is passage-dependent and
absent in preswollen cells. Cells were grown in serum enriched media and
after reaching sub confluence, apelin was added for 6 h in the treatment group.
Furthermore, apelin was present for additional 20 min during flux; whereas, the
control group contained no apelin. Panel (A) Percent (%) apelin-mediated
increase in KCC activity in pre-shrunken cells subsequently swollen (cells that
were first exposed to hypertonic solution during preincubation (10 min) and then
in hypotonic solution (20 min) during flux (450  120 mOSM), and Panel (B)
Percent (%) apelin-mediated increase or decrease in KCC activity in pre-swollen
cells subsequently shrunken (cells that were first exposed to hypotonic solution
during preincubation and then in hypertonic solution during flux (120  450
mOSM). For each VSMCs passage, apelin response was normalized to that of
the control. Data represents mean ± standard error of three independent
experiments, n = 6 per conditions. *p < 0.05 vs control group.
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Table 3. Summary of apelin effect on K-Cl cotransport in VSMCs. Under
isotonic conditions, acute treatment of apelin-13 in serum-starved VSMCs
stimulated KCC activity in the presence of extracellular sodium. In the absence of
serum deprivation (serum-fed cells) apelin-13 treatment significantly increased KCl cotransport in contractile VSMCs. In contrast, in synthetic VSMCs, apelin-13
did not promote KCC activity under isotonic conditions. Similarly, in the absence
of extracellular sodium no stimulatory effect of apelin was observed. Stimulation
of K-Cl cotransport activity can be observed in serum-fed synthetic VSMCs under
hypotonic conditions when apelin is present in growth and flux media. This mode
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of activation was not seen at longer incubation times (24 h) probably due to APJ
desensitization. Finally, KCC activity from serum-fed synthetic VSMCs was up
regulated when cells were transferred from hypertonic to hypotonic conditions.
Importantly, apelin stimulated KCC activity only when apelin was present in the
flux media (acute activation); no stimulation of K-Cl cotransport was seen after
chronic apelin exposure times in serum-starved cells.
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Figure 47. Schematic hypothetical representation of apelin regulation of KCl cotransport in VSMCs. In VSMCs, the binding of apelin-13 to its receptor
APJ, activates K-Cl cotransport by increasing KCC protein expression and
possibly increased membrane trafficking (1). Additionally, apelin-13 elicits the
activation of several signaling cascades including PI3K/Akt, NO/cGMP/PKG1 and
ERK1/2 to sustain KCC activation (2). Apelin-13-mediated activation of KCC
occurs under both, hypertonicity and hypotonicity. In normal conditions,
hypotonicity and RVD stimulate K-Cl cotransport through activation of protein
phosphatases like PP1 and PP2A. It is possible that apelin administration results
in PP1 and PP2A stimulation in order to sustain KCC activation (4). During
hypertonicity, KCC activity is inhibited by phosphorylation events and activation
of serine threonine kinases including WNK and SPAK (4). The apelin-13129

mediated activation of K-Cl cotransport is dependent on the presence of serum in
the growth media, ionic strength and is central to control cell proliferation and
migration which are required to sustain VSMCs phenotypic switching.
Importantly, apelin-13 administration is able to rescue the oxLDL mediated
inhibition of KCC.
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DISCUSSION: Specific Aims 2 and 3
Apelin/APJ has emerged as an important regulator of cellular homeostasis and
cardiovascular function. By targeting apelin/APJ, and subsequent stimulation of
several signaling cascades such as the NO/cGMP/PKG, PI3K/Akt and ERK (1/2),
a coordinated cardio-protective multicellular response takes place to repair and
prevent further cell damage (53, 63, 197-199). Migration of VSMCs and their
transition from contractile to synthetic states constitute initial steps to aid in the
repair of atherosclerotic endothelium. Failure of VSMCs to switch back to
contractile states accelerates lesion formation and results counterproductive due
to possible increases in inflammatory processes (29). Although, further research
is required to fully understand the inability of VSMCs to return to contractile
states, in general, it has become evident that dysregulations in cell proliferation
(mostly caused by high levels of growth factors, and uncontrolled uptake of
oxLDL) are involved in the molecular pathogenesis of atherosclerosis (42, 47).

Several lines of evidence have pointed out that common signaling networks
regulate the activity of KCC and the apelin-mediated cardio-protective effects
(53, 105, 150, 157, 160, 184). Here we have provided evidence to support that
electroneutral K-Cl cotransport in VSMCs is responsive to apelin via its
membrane receptor APJ. Although differences were found in the APJ subcellular
localization between synthetic (homogenously distributed) and contractile

131

VSMCs (perinuclear, localization), in general, the apelin receptor was found
abundantly expressed in contractile and synthetic VSMCs (Figure 28C-D).
Apelin treatment stimulated K-Cl cotransport irrespective of VSMCs phenotype.
These results suggest a rapid trafficking of APJ to the membrane in order to elicit
a comparable response in synthetic and contractile VSMCs. Although further
experiments will be required to determine whether apelin could change the APJ
subcellular localization, it is likely that increased APJ membrane trafficking
facilitates apelin signaling in VSMCs (200, 201). In addition, further research will
be required to confirm whether APJ is present in endosomes or any other
subcellular compartment (202).

Our results also indicate an intricate overlap among several signaling cascades
(NO/cGMP/PKG, PI3K/Akt and ERK1/2) to coordinate the apelin-mediated
effects on KCC activity. Although selective inhibition of PKG, Akt and ERK1/2
completely prevented the apelin stimulatory-effect on the K-Cl cotransport in
VSMCs (Figures 31-32); further examination will be required to determine the
exact degree of contribution of each signaling cascade and their relevance to
sustain vascular tone and endothelial function in vivo. Based on previous studies
by our laboratory and others, in which PKG expression has proven to be absent
in synthetic VSMCs (132), it is possible that differential regulation of KCCs’
activity might occur within VSMCs phenotypes. Contractile VSMCs could be
more dependent on the NO/cGMP/PKG pathway to respond to apelin, whereas
in synthetic VSMCs, apelin could elicit its effects mostly through PI3K/Akt and
ERK1/2 signaling cascades. It remains to be studied whether apelin treatment
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results in an increase of KCCs expression/turnover, more efficiently trafficking to
the plasma membrane or posttranslational modifications that promote an
increase

in

KCCs

activity.

For

years

it

has

been

recognized

that

phosphorylation/dephosphorylation events greatly determine the activity of
NKCCs and KCCs. Consistent with their coordinated role in modulating
intracellular chloride concentration, reciprocal modes of activation govern their
activity. Increased activity of serine threonine kinases such as members of the
WNK family (WNK 1-4) and Ste20 (SPAK and OSR1) enhance NKCCs activity
and decrease KCCs function. Similarly, up regulation of protein phosphatases
(PP1 and PP2B) inhibit NKCCs and activate KCCs. Therefore, it is likely that
dephosphorylation of serine and threonine residues within the KCCs carboxy
terminus constitute final events in the apelin stimulatory effect on KCCs (146).

Studies have shown that apelin and oxLDL have opposite effects on
cardiovascular function. In CVD low levels of circulating apelin have been
observed (203). Similarly, it has been recently shown that low plasma apelin
concentrations constitute a risk to develop atrial fibrillation (204). Even though
atherosclerosis is caused and sustained by a plethora of factors, the increasing
evidence pointing out apelin administration as a remarkable protective therapy
against atherosclerotic lesions is fully supported by our observations. Here we
showed that apelin treatment restored the oxLDL-inhibitory effect on KCCs
activity in contractile VSMCs (Figure 31B). Since high levels of oxLDL have
shown in one hand to promote an increase in KCC1 mRNA expression (166) and
simultaneously inhibit K-Cl cotransport in our studies (Figure 31B), it has not
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escaped our notice that the increased mRNA levels for KCC could be part of a
compensatory mechanism to attempt restore VSMCs’ migration and normal cell
volume.
Perhaps the most intriguing findings in these studies constitute the variability in
the apelin-mediated effect on K-Cl cotransport. These differences were related to
changes in external Na+, serum and phenotypic states. In summary, serum-fed
cells in the presence of external Na+ displayed activation of K-Cl cotransport
under hypo- and hypertonic conditions. In the absence of extracellular Na +, no
stimulatory effect by apelin was observed. To date it remains to be determined
how extracellular Na+ could be modulating the originally described sodium
independent K-Cl cotransport.
Additionally, our data highlights apelin’s role to modulate KCC activity in
response to changes in extracellular osmolality (Figures 37B, 43-45). In both,
synthetic and contractile VSMCs, apelin treatment resulted in further stimulation
under hypotonic/swelling conditions (Figure 37B and 43-44). Studies have
shown that hypotonic stimuli result in cell swelling and decreased lumen
diameters (205). Noteworthy, hypotonic conditions also promote KCC activation;
all of the above highlights increase in KCC activity as responsible for the apelinmediated cardioprotective effects. The above has clinical implications since
increased K-Cl cotransport and therefore vasorelaxation are commonly seen
after exposure to hydralazine (HYZ), a vasodilator that has been shown to
reduce tension of the vascular smooth muscle through increase in K-Cl
cotransport activity (152). The effect of hydralazine can be mirrored to the apelin
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response under hypotonic stimuli in VSMCs. Altogether our findings highlight
increases in KCC activity as important effectors in sustaining normal vascular
tone. 
Under hypertonic/shrinking conditions, apelin treatment significantly increased
KCCs activity and bypassed the osmolality-mediated inhibition of KCCs in
synthetic VSMCs (Figure 37B). To our knowledge, this is the first time an
extracellular stimulus bypasses the osmolality-mediated regulation on KCCs
activity. Studies have shown that cell shrinkage results in increased lumen
diameters and thus, stimulation of apelin response in hypertonic condition might
be beneficial in maintenance of vessel relaxation in vivo (206). Consistently,
absence of stimulation by apelin was observed when pre-swollen VSMCs were
exposed to hypertonic media (shifted from 120 to 450 mOSM). In contrast, when
pre-shrunken VSMCs were exposed to hypotonic stimuli (shifted from 450 to 120
mOSM); apelin treatment resulted in significant increase of KCCs. Based on
published reports, it is likely that serine and threonine residues within KCCs
carboxy terminus constitute final targets in the apelin stimulatory effect on KCCs
(146, 207). Altogether these findings place apelin as a master regulator of cell
volume and highlight its role during osmosensing processes.

KCC is involved in ionic balance and cellular homeostasis. Apelin and its
receptor are also implicated in fluid homeostasis (52, 64, 72). The mechanisms
by which apelin promotes fluid and cellular homeostasis by regulating ion
transporters are less understood. Thus, the third specific aim of the thesis sought
to test the hypothesis that apelin may promote cellular homeostasis through its
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action on KCC and by modulating its transport activity. This homeostatic
mechanism is important for overall vascular function. Finally, the close
association between cell proliferation and volume regulation suggests that K-Cl
cotransport activity and its regulation by apelin, are both important to confer
protection against atherosclerosis. A better understanding of apelin effects on KCl cotransport will help design a more powerful therapeutic approach to treat
atherosclerosis-linked cardiovascular diseases.
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CONCLUSION
The work presented in this thesis offers compelling evidence supporting that
apelin/APJ constitutes an important modulator of electroneutral K-Cl cotransport
in rat aortic vascular smooth muscle cells. Increased K-Cl cotransport activity,
measured by atomic absorption spectrometry, was determined under isotonic
condition, in both contractile and synthetic VSMCs when exposed to 1 µM of the
most abundant form of apelin found in the circulatory system (apelin-13). In
contrast, no stimulatory effect on K-Cl cotransport was observed when apelin
was present in serum-free growth media before flux measurements.

By using selective inhibitors of PKG, PI3K and MAPK signaling pathways, such
as KT5823, LY294002, and PD98059, we demonstrated that under isotonic
conditions, apelin-13 increased K-Cl cotransport in serum-starved VSMCs
through activation of those signaling cascades. Our data also suggests
differences in expression and subcellular localization of APJ among VSMCs
phenotypes. APJ total expression was decreased in synthetic VSMCs. Its
expression appeared more diffused and cytoplasmic when compared to
contractile VSMCs where a more localized and perinuclear immunolocalization
could be observed.

We showed that K-Cl cotransport in VSMCs is dramatically impaired (~ 70 % of
inhibition) by oxLDLs, a known promoter of vascular lesions and atherosclerosis
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progression. Importantly, apelin treatment prevented the oxLDL-mediated
inhibition of K-Cl cotransport since similar activation was observed in response to
apelin. These findings are in accordance with the protective roles of apelin
against cardiovascular disease (CVD).

However, variability in the apelin response was observed among VSMCs
phenotypes. K-Cl cotransport activity is more prone to activation by apelin in
serum-fed compared to serum-starved VSMCs. Besides, extracellular sodium
was required for apelin to modulate KCC activity. Additionally, apelin’s role in
controlling K-Cl cotransport proved to be of central importance since stimulation
of KCC activity was enhanced under hypotonic and hypertonic conditions. Similar
stimulatory effect of apelin was observed when pre-shrunken VSMCs were
swollen. In sum, these results highlight apelin’s role in controlling cellular
homeostasis and place KCC activity as an important therapeutic target) and
potential mediator in the apelin-conferred protection against CVD.
In addition, we found that expression levels of cytoskeletal protein markers like αactin, vimentin, and desmin decreased in late synthetic stages. Finally we also
showed that both, the apparent Rb+ and Cl- affinities and Vmax values of KCC
increased in late synthetic VSMCs compared to earlier states. Consistently,
increased protein expression of KCC1 and KCC4 were observed in late synthetic
VSMCs compared to earlier states. These results point out that the functional
properties of KCC may be involved and required to sustain VSMCs phenotypic
switching and their transition to a diseased state during CVD, perhaps as a
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compensatory mechanism trying to overcome the ravages of this serious
disease.
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